<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC10732420</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0293700</article-id><article-id pub-id-type="publisher-id">PONE-D-23-23018</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Breast Tumors</subject><subj-group><subject>Breast Cancer</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Treatment</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Metastasis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Basic Cancer Research</subject><subj-group><subject>Metastasis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Lung and Intrathoracic Tumors</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Nephrology</subject><subj-group><subject>Renal Cancer</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Imaging Techniques</subject><subj-group><subject>In Vivo Imaging</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Diagnostic Radiology</subject><subj-group><subject>Bone Imaging</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Imaging Techniques</subject><subj-group><subject>Diagnostic Radiology</subject><subj-group><subject>Bone Imaging</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Radiology and Imaging</subject><subj-group><subject>Diagnostic Radiology</subject><subj-group><subject>Bone Imaging</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Animal Studies</subject><subj-group><subject>Experimental Organism Systems</subject><subj-group><subject>Model Organisms</subject><subj-group><subject>Mouse Models</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Model Organisms</subject><subj-group><subject>Mouse Models</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Animal Studies</subject><subj-group><subject>Experimental Organism Systems</subject><subj-group><subject>Animal Models</subject><subj-group><subject>Mouse Models</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Transferrin receptor in primary and metastatic breast cancer: Evaluation of expression and experimental modulation to improve molecular targeting</article-title><alt-title alt-title-type="running-head">Transferrin, molecular imaging, targeting, TfR, metastases, deferoxamine, iron, breast cancer</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5889-9413</contrib-id><name><surname>Fontana</surname><given-names>Francesca</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Esser</surname><given-names>Alison K.</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Egbulefu</surname><given-names>Christopher</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Karmakar</surname><given-names>Partha</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Su</surname><given-names>Xinming</given-names></name><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Allen</surname><given-names>John S.</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Yalin</given-names></name><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Davis</surname><given-names>Jennifer L.</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gabay</surname><given-names>Ariel</given-names></name><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Xiang</surname><given-names>Jingyu</given-names></name><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kwakwa</surname><given-names>Kristin A.</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Manion</surname><given-names>Brad</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bakewell</surname><given-names>Suzanne</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Shunqiang</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Haeseong</given-names></name><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lanza</surname><given-names>Gregory M.</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Achilefu</surname><given-names>Samuel</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7137-4742</contrib-id><name><surname>Weilbaecher</surname><given-names>Katherine N.</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States of America</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Radiology, Washington University School of Medicine, St. Louis, MO, United States of America</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Pantopoulos</surname><given-names>Kostas</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>Lady Davis Institute for Medical Research, CANADA</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>no authors have competing interests</p></fn><corresp id="cor001">* E-mail: <email>kweilbae@wustl.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>18</volume><issue>12</issue><elocation-id>e0293700</elocation-id><history><date date-type="received"><day>9</day><month>8</month><year>2023</year></date><date date-type="accepted"><day>17</day><month>10</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; 2023 Fontana et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Fontana et al</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0293700.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Conjugation of transferrin (Tf) to imaging or nanotherapeutic agents is a promising strategy to target breast cancer. Since the efficacy of these biomaterials often depends on the overexpression of the targeted receptor, we set out to survey expression of transferrin receptor (TfR) in primary and metastatic breast cancer samples, including metastases and relapse, and investigate its modulation in experimental models.</p></sec><sec id="sec002"><title>Methods</title><p>Gene expression was investigated by datamining in twelve publicly-available datasets. Dedicated Tissue microarrays (TMAs) were generated to evaluate matched primary and bone metastases as well as and pre and post chemotherapy tumors from the same patient. TMA were stained with the FDA-approved MRQ-48 antibody against TfR and graded by staining intensity (H-score). Patient-derived xenografts (PDX) and isogenic metastatic mouse models were used to study <italic toggle="yes">in vivo</italic> TfR expression and uptake of transferrin.</p></sec><sec id="sec003"><title>Results</title><p><italic toggle="yes">TFRC</italic> gene and protein expression were high in breast cancer of all subtypes and stages, and in 60&#x02013;85% of bone metastases. TfR was detectable after neoadjuvant chemotherapy, albeit with some variability. Fluorophore-conjugated transferrin iron chelator deferoxamine (DFO) enhanced TfR uptake in human breast cancer cells in vitro and proved transferrin localization at metastatic sites and correlation of tumor burden relative to untreated tumor mice.</p></sec><sec id="sec004"><title>Conclusions</title><p>TfR is expressed in breast cancer, primary, metastatic, and after neoadjuvant chemotherapy. Variability in expression of TfR suggests that evaluation of the expression of TfR in individual patients could identify the best candidates for targeting. Further, systemic iron chelation with DFO may upregulate receptor expression and improve uptake of therapeutics or tracers that use transferrin as a homing ligand.</p></sec></abstract><funding-group><award-group id="award001"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap>
</funding-source><award-id>P01 CA100730</award-id></award-group><award-group id="award002"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap>
</funding-source><award-id>R01 CA216840</award-id></award-group><award-group id="award003"><funding-source>
<institution>US Department of Defense</institution>
</funding-source><award-id>BCRP W81XWH16 1-0286</award-id></award-group><award-group id="award004"><funding-source>
<institution>NIH</institution>
</funding-source><award-id>5T32CA113275-07 and 5F32CA189671-02</award-id><principal-award-recipient>
<name><surname>Esser</surname><given-names>Alison K.</given-names></name>
</principal-award-recipient></award-group><award-group id="award005"><funding-source>
<institution>Children&#x02019;s Discovery Institute of Washington University</institution>
</funding-source><award-id>CDI-CORE-2015-505, CDI-CORE-2019-813</award-id></award-group><award-group id="award006"><funding-source>
<institution>St. Louis Children&#x02019;s Hospital</institution>
</funding-source><award-id>N/A</award-id></award-group><award-group id="award007"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100007338</institution-id><institution>Foundation for Barnes-Jewish Hospital</institution></institution-wrap>
</funding-source><award-id>3770 and 4642</award-id></award-group><award-group id="award008"><funding-source>
<institution>S10</institution>
</funding-source><award-id>RR027552</award-id></award-group><award-group id="award009"><funding-source>
<institution>ICTS</institution>
</funding-source><award-id>N/A</award-id></award-group><award-group id="award010"><funding-source>
<institution>UL1</institution>
</funding-source><award-id>TR002345</award-id></award-group><award-group id="award011"><funding-source>
<institution>Pat Burkhardt Breast Cancer Research Fund</institution>
</funding-source><award-id>N/A</award-id></award-group><award-group id="award012"><funding-source>
<institution>St. Louis Men's Group Against Cancer</institution>
</funding-source><award-id>N/A</award-id></award-group><award-group id="award013"><funding-source>
<institution>BioRender</institution>
</funding-source><award-id>N/A</award-id></award-group><funding-statement>Funding for this project was provided by the National Cancer Institute (NCI), NIH, P01 CA100730; NCI R01 CA216840; US Department of Defense (DoD) BCRP W81XWH16 1-0286. AE received support from NIH grants 5T32CA113275-07 and 5F32CA189671-02. Cores used in this project were funded by Children&#x02019;s Discovery Institute of Washington University and St. Louis Children&#x02019;s Hospital CDI-CORE-2015-505, CDI-CORE-2019-813, the Foundation for Barnes-Jewish Hospital 3770 and 4642; S10 RR027552; ICTS, UL1 TR002345, the Pat Burkhardt Breast Cancer Research Fund, the St. Louis Men's Group Against Cancer, and BioRender for graphics. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="7"/><table-count count="0"/><page-count count="29"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All original data is included in the paper and <xref rid="sec025" ref-type="sec">Supporting Information</xref> Files. Gene expression data is from publicly available datasets, which are referenced and easily accessible.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All original data is included in the paper and <xref rid="sec025" ref-type="sec">Supporting Information</xref> Files. Gene expression data is from publicly available datasets, which are referenced and easily accessible.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>1. Introduction</title><p>In the United states, breast cancer is the second leading cause of cancer death in women [<xref rid="pone.0293700.ref001" ref-type="bibr">1</xref>], in Europe the first [<xref rid="pone.0293700.ref002" ref-type="bibr">2</xref>]. The main cause of death is the development of metastases which cause 5-year survival numbers to drop from 85% [<xref rid="pone.0293700.ref003" ref-type="bibr">3</xref>] to 22&#x02013;8% [<xref rid="pone.0293700.ref004" ref-type="bibr">4</xref>]. Identification and treatment of systemic disease in breast cancer patients are crucial to improve treatment and survival. Molecular imaging and nanotherapy represent promising strategies to efficiently locate and reach all tumor foci by relying on the over-expression of targetable surface proteins by cancer cells.</p><p>Transferrin Receptor (TfR, TfR1, <italic toggle="yes">TFRC</italic>) is a membrane protein commonly overexpressed by cancer cells [<xref rid="pone.0293700.ref005" ref-type="bibr">5</xref>&#x02013;<xref rid="pone.0293700.ref007" ref-type="bibr">7</xref>], making it an appealing target for anti-cancer biomaterials such as molecular probes or nanoparticles [<xref rid="pone.0293700.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0293700.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0293700.ref008" ref-type="bibr">8</xref>&#x02013;<xref rid="pone.0293700.ref014" ref-type="bibr">14</xref>]. Its physiological function is to allow cellular intake of iron, safely bound to transferrin. While systemic iron metabolism involves high liver expression of transferrin receptor 2 (<italic toggle="yes">TFR2</italic>), TfR is present in all cells, and its expression responds to the cell&#x02019;s metabolic requirements, for example through transcriptional regulation by iron responsive proteins (IRP1 and IRP2) [<xref rid="pone.0293700.ref015" ref-type="bibr">15</xref>]. To sustain increased iron demand for catalysis and biogenesis [<xref rid="pone.0293700.ref016" ref-type="bibr">16</xref>], tumor cells often overexpress TfR, which can be directly regulated by oncogenic pathways such as c-Myc and Ras [<xref rid="pone.0293700.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0293700.ref016" ref-type="bibr">16</xref>&#x02013;<xref rid="pone.0293700.ref018" ref-type="bibr">18</xref>].</p><p>Transferrin was identified as a key factor for breast cancer cell survival about 40 years ago [<xref rid="pone.0293700.ref019" ref-type="bibr">19</xref>], and TfR was shown to be upregulated in breast cancer [<xref rid="pone.0293700.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0293700.ref016" ref-type="bibr">16</xref>] relative to normal breast or fibromas [<xref rid="pone.0293700.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0293700.ref021" ref-type="bibr">21</xref>]. Since then, preclinical models or early-stage clinical studies have addressed the potential of conjugating transferrin to chemotherapeutics [<xref rid="pone.0293700.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0293700.ref012" ref-type="bibr">12</xref>], drug-carrying nanoparticles [<xref rid="pone.0293700.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0293700.ref022" ref-type="bibr">22</xref>&#x02013;<xref rid="pone.0293700.ref024" ref-type="bibr">24</xref>], and optical [<xref rid="pone.0293700.ref025" ref-type="bibr">25</xref>&#x02013;<xref rid="pone.0293700.ref027" ref-type="bibr">27</xref>] or radioactive [<xref rid="pone.0293700.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0293700.ref010" ref-type="bibr">10</xref>] tracers to target breast cancer.</p><p>Targeting agents often rely on membrane expression of the receptor in tumor cells, which would bind more ligand than non-tumor cells improving specificity [<xref rid="pone.0293700.ref028" ref-type="bibr">28</xref>]. In order to facilitate translation of transferrin-conjugated probes and therapeutics in breast cancer, we set out to characterize the expression of TfR throughout large datasets and [<xref rid="pone.0293700.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0293700.ref025" ref-type="bibr">25</xref>, <xref rid="pone.0293700.ref026" ref-type="bibr">26</xref>] ad-hoc collections of breast cancer histological specimens, with a particular focus on the inclusion of post-chemotherapy and metastatic lesions, which are often underrepresented in discovery studies. Addressing the dynamic relationship between the regulation of the receptor and the uptake of biomaterials, we then asked whether iron-responsive regulation of transferrin could be used to increase the uptake of transferrin conjugates in breast cancer cell lines <italic toggle="yes">in vitro</italic> and improve transferrin accumulation at breast metastatic sites <italic toggle="yes">in vivo</italic>. Our results confirm the frequent overexpression of transferrin receptor in all clinical and pathological classes of breast cancer, but also show variability between patients and even individual cells within the same tumor. Further, in vitro and in vivo evidence suggests that deferoxamine (DFO), an FDA-approved iron chelator under investigation for the treatment of breast cancer [<xref rid="pone.0293700.ref029" ref-type="bibr">29</xref>&#x02013;<xref rid="pone.0293700.ref033" ref-type="bibr">33</xref>], can enhance uptake of transferrin conjugates by metastatic breast cancer. Overall, this suggests that the efficacy of transferrin receptor targeting may be improved in two ways: (1) by confirming the overexpression in the tumors of individual patients by molecular imaging, and (2) by modulating iron availability to increase expression of TfR by cancer cells.</p></sec><sec sec-type="materials|methods" id="sec006"><title>2. Materials and methods</title><sec id="sec007"><title>2.1 Data mining</title><p>Data on cancer vs normal and breast cancer subtypes were obtained from the GENT2 (Gene expression database of Normal and Tumor tissues [<xref rid="pone.0293700.ref034" ref-type="bibr">34</xref>]). Clinical and gene expression data from The Cancer Genome Atlas (TCGA) breast cancer set [<xref rid="pone.0293700.ref035" ref-type="bibr">35</xref>] were downloaded from the UCSC Xena genome explorer [<xref rid="pone.0293700.ref036" ref-type="bibr">36</xref>]. Conversion from gene ID to microarray probes was performed by downloading platform translations from the Gemma database [<xref rid="pone.0293700.ref037" ref-type="bibr">37</xref>]. Datasets GSE153470 [<xref rid="pone.0293700.ref038" ref-type="bibr">38</xref>], GSE114082 [<xref rid="pone.0293700.ref039" ref-type="bibr">39</xref>], GSE21974 [<xref rid="pone.0293700.ref040" ref-type="bibr">40</xref>], GSE18728 [<xref rid="pone.0293700.ref041" ref-type="bibr">41</xref>], GSE111151 [<xref rid="pone.0293700.ref042" ref-type="bibr">42</xref>], GSE58708 [<xref rid="pone.0293700.ref043" ref-type="bibr">43</xref>], GSE62598 [<xref rid="pone.0293700.ref044" ref-type="bibr">44</xref>], GSE130788 [<xref rid="pone.0293700.ref045" ref-type="bibr">45</xref>], GSE165393 [<xref rid="pone.0293700.ref046" ref-type="bibr">46</xref>], GSE175692 [<xref rid="pone.0293700.ref047" ref-type="bibr">47</xref>], and GSE43837 [<xref rid="pone.0293700.ref048" ref-type="bibr">48</xref>] were obtained from the Gene Expression Omnibus (GEO) database [<xref rid="pone.0293700.ref049" ref-type="bibr">49</xref>]. Single cell RNA-sequencing (scRNAseq) breast cancer dataset in Chung et al. [<xref rid="pone.0293700.ref050" ref-type="bibr">50</xref>] was analyzed visualizing clusters based on histology subtype wth Cell Expression Atlas (EMBL-EBI [<xref rid="pone.0293700.ref051" ref-type="bibr">51</xref>]). Data on transferrin receptor 1 (<italic toggle="yes">Tfrc</italic>) and transferrin receptor 2 (<italic toggle="yes">Tfr2</italic>) from normal mouse tissue was obtained for 3 different datasets from the Expression Atlas (www.ebi.ac.uk/gxa) [<xref rid="pone.0293700.ref052" ref-type="bibr">52</xref>].</p></sec><sec id="sec008"><title>2.2 Tissue banking and consent</title><p>Patient samples from the St. Louis Breast Tissue Registry (<ext-link xlink:href="https://breasttissue.wustl.edu/" ext-link-type="uri">https://breasttissue.wustl.edu</ext-link>) were obtained and accessed in accordance with the guidelines established by the Washington University&#x02019;s Institutional Review Board (IRB #201102394) and WAIVER of Elements of Consent as per 45 CFR 46.116 (d). All patient information was deidentified prior to investigator use. All of the human research activities and all activities of the IRBs designated in the Washington University Federal Wide Assurance, regardless of sponsorship, are guided by the ethical principles in "The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects Research of the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research."</p></sec><sec id="sec009"><title>2.3 Immunohistochemistry (IHC) and histomorphometry</title><p>Tissue microarrays were generated from the St. Louis Breast Tissue Registry (<ext-link xlink:href="https://breasttissue.wustl.edu/" ext-link-type="uri">https://breasttissue.wustl.edu</ext-link>) as described in Ross et al. [<xref rid="pone.0293700.ref053" ref-type="bibr">53</xref>] with breast cancer samples and non-breast control tissues, and quality checked by a board-certified pathologist. Samples were hybridized with the MRQ-48 monoclonal anti-human CD71 antibody [<xref rid="pone.0293700.ref054" ref-type="bibr">54</xref>] (FDA-GS1 #00841683101185) produced and validated by eBioscience (cat #14&#x02013;0718), and developed with the EnVision+ System-HRP (Dako) according to the manufacturer&#x02019;s protocol. Commercially available tissue microarrays (TMA) #MTU951, #BC081116c, #BC081116c (US BioMax Inc) were used to validate the protocol and showed increased staining in cancer samples relative to matching non-tumor tissue (not shown). Slides were counterstained with hematoxylin, and scanned on the Zeiss AxioScan.Z1 microscope.</p><p>Breast cancer subtyping was based on estrogen receptor (ER), progesterone receptor (PR), and human epithelial growth factor receptor 2 (HER2) status, assessed by the diagnosing pathologist, and classifying as luminal A tumors that were ER+,PR&#x000b1;,HER2&#x02212; (<italic toggle="yes">n</italic> = 39), luminal B for ER+,PR&#x000b1;,HER2+ (<italic toggle="yes">n</italic> = 17), HER2-enriched for ER&#x02212;,PR&#x02212;,HER2+ (<italic toggle="yes">n</italic> = 19), and triple-negative (TNBC) for ER&#x02212;,PR&#x02212;,HER2&#x02212; (<italic toggle="yes">n</italic> = 23) tumors. Eight breast carcinomas had incomplete genetic subtyping and were excluded from the subtype analysis.</p><p>Tumor-associated TfR (CD71) expression was semi-quantitatively scored using the histo-score (H-score) system: H-score = &#x02211;(i x %) [<xref rid="pone.0293700.ref055" ref-type="bibr">55</xref>], where &#x0201c;i&#x0201d; is the staining intensity (0&#x02013;3 scale), and &#x0201c;%&#x0201d; is the percentage of tumor cells stained at each intensity.</p></sec><sec id="sec010"><title>2.4 Animal models</title><p>Animal studies were approved by the Washington University Institutional Animal Care and Use Committee (IACUC) and are reported according to the ARRIVE guidelines. TfR expression was assessed in archived tissues from mouse tumor models [<xref rid="pone.0293700.ref053" ref-type="bibr">53</xref>, <xref rid="pone.0293700.ref056" ref-type="bibr">56</xref>].</p><p>For Patient-Derived Xenograft (PDX) experiments, 10 NSG mice were implanted with WHIM68 and 9 with WHIM69 breast cancer cell lines subcutaneously as previously described [<xref rid="pone.0293700.ref057" ref-type="bibr">57</xref>] and treated with Taxol (30mg/kg) and carboplatin (50mg/kg) or vehicle. Mice implanted with WHIM68 were treated on days 30, 37, and 44; mice implanted with WHIM69 on days 44, 51, and 58. Eight mice implanted with WHIM68 (N = 5 vehicle and N = 3 NAC) were sacrificed on day 57, and mice with regrowing tumors (relapse N = 2) were euthanized on day 148. Mice injected with WHIM69 (N = 5) and treated with vehihcle (N = 3) were sacrificed on day 62, while NAC mice were sacrificed on day 111 (N = 2), and relapse at day 192 (N = 2) [<xref rid="pone.0293700.ref057" ref-type="bibr">57</xref>].</p><p>To establish diffuse/metastatic triple negative breast cancer 0.5x10<sup>5</sup> 4T1 tumor cells were injected during general anesthesia into the left ventricle 6-week-old BALB/cJ (4T1) female mice (Jackson Laboratories). For diffuse luminal B cancer, 0.5x10<sup>5</sup> MMTV-Bo1-Luc-GFP cells were injected in the left ventricle of C57Bl/6 female mice of 5&#x02013;6 weeks of age (under general anesthesia). Development of metastases was monitored in vivo total body BLI.</p><p>Ferritin was measured in serum samples by ELISA according to manufacturer protocol (Mouse Ferritin ELISA kit, Crystal Chem, Elk Grove Village, IL), and optical density was recorded with a SpectraMax microplate reader (Molecular Devices, San Jose, CA).</p></sec><sec id="sec011"><title>2.5 In vivo and ex-vivo imaging</title><p>Transferrin-Vivo 750 (PerkinElmer, Waltham, MA, referred to as AF750-Tf) was injected i.v. according to manufacturer instructions 24 hours prior to sacrifice and dual BLI/optical imaging. Average radiance (photons/sec/cm<sup>2</sup>) and average radiant efficiency were measured from fixed regions of interest (ROIs) using Living Image 2.6 (PerkinElmer, Waltham, MA).</p><p>Ex-vivo optical imaging of organs and tissues was performed and average radiant efficiency was measured in the heart, lungs, spleen, kidneys, liver, gut, brain, white adipose tissue (WAT) deposits in the abdomen (gonadal) and subcutaneous (including the mammary fat pad), brown adipose tissue (BAT) from the intrascapular region, muscles (femoral quadriceps), and bones (legs, spine, pelvic gridle).</p><p>At 11&#x02013;12 days post implantation, 4T1 tumor-bearing and non-tumor bearing mice (N = 5) were injected i.v. with Transferrin-AlexaFluor 680 (ThermoFisher, <ext-link xlink:href="https://www.google.com/search?client=safari&#x00026;rls=en&#x00026;sxsrf=AJOqlzVsM3h504uNCmqWjqtA97vIF4FzwQ:1675883445684&#x00026;q=Waltham&#x00026;si=AEcPFx6l3RvH8SFlhHZyn7jIc6m2bU9vmoFvFAMQv2WWSYjXN8Aa11LoAMedq3c7biwJo4P_6AD0U2hy4zRorV6vC-gW4Y9EqRuA4Nn7eUDwjX4rI3fCwfzePc9Lg4IMDEjOWCK9Cix_kSSmrLP9Ix6LBMcviEjHTUc0EJa23n1Nf0dWXBNijOzJQ-DRhmyYc0jPKC4bKlF3&#x00026;sa=X&#x00026;ved=2ahUKEwie4Nur0Ib9AhW9j4kEHRkFAbkQmxMoAXoECGQQAw" ext-link-type="uri">Waltham, MA</ext-link>) imaging agent and then followed by mice imaging at 0, 2, 6 and 24 h time-points using the fluorescence molecular tomography (FMT 4000, PerkinElmer, Waltham, MA) and the Pearl NIR small animal imager (Li-Cor Biosciences Inc., Lincoln, NE, USA) in vivo. Following euthanasia with 5% isoflurane (as in American Medical Veterinary Association guidelines) ex-vivo imaging was performed at 6h or 24h using the Pearl NIR imager and the IVIS50 bioluminescence image (PerkinElmer, Waltham, MA) as previously described [<xref rid="pone.0293700.ref058" ref-type="bibr">58</xref>]. The mean fluorescence intensity (MFI) and the total photon flux (photons/sec) for each organ was estimated using the Pearl and IVIS50 software, respectively and summarized using a bar plot &#x000b1; SEM (n = 5 per group).</p><p>Deferoxamine mesylate (Sigma, DFO) was administered by i.p. injection. Lack of treatment-related toxicity was verified in two preliminary experiments by administering to C57Bl/6 100mg/kg (N = 2) versus 200mg/kg daily (N = 2) for 8 days.</p><p>To model the effects of DFO treatment in. Mice were randomized to receive vehicle (HBSS, N = 4-5/experiment, total N = 9) or DFO 200mg/kg (N = 5-6/experiment, total N = 11).</p></sec><sec id="sec012"><title>2.6 In vitro experiments</title><p>The murine C57BL/6 PyMT-Bo1 luminal B breast cancer and 4T1-GFP-Luc cell line expressing green fluorescent protein (GFP) and firefly luciferase (Luc) were originated and tested as described (Su [<xref rid="pone.0293700.ref058" ref-type="bibr">58</xref>] and David Piwnica-Worms lab [<xref rid="pone.0293700.ref059" ref-type="bibr">59</xref>]). T4D1 and MCF-7 were obtained from ATCC. Low-passage stocks were used and regularly tested for Mycoplasma and maintenance of growth characteristics. Modulation of extracellular iron was obtained in vitro by treating cells with Ferric Ammonium Citrate (FAC, Sigma) or Deferoxamine (DFO, Sigma) 80-200&#x003bc;mol/L for 24 to 48h. Transferrin uptake in vitro was assessed by incubation with transferrin from human serum Alexa Fluor<sup>TM</sup> 488 conjugate (Thermo Fisher T13342) according to manufacturer&#x02019;s instructions and analyzed for fluorescence excitation/emission wavelengths of 485/506 nm with a SpectraMax microplate reader (Molecular Devices, San Jose, CA). For normalization, nuclei were counter-stained with Hoechst (co-registering fluorescence at 361-450nm) or by crystal violet measuring 570nm optical density. PhRodo<sup>TM</sup> Red transferrin conjugate (Thermo Fisher, P35376) and nuclear staining with Hoechst were used for assessment of endocytosis of Tf. Live cell images were acquired with an inverted stage microscope (Nikon E800, DIAPHOT300), and images merged with ImageJ (imagej.nih.gov/ij).</p></sec><sec id="sec013"><title>2.7 Statistics</title><p>Power analysis was performed using G*power 3 [<xref rid="pone.0293700.ref035" ref-type="bibr">35</xref>] for sample size determination of two group comparisons [<xref rid="pone.0293700.ref060" ref-type="bibr">60</xref>]. For power of multi-group analyses, we used the open-access sample size calculator v1.058 (<ext-link xlink:href="https://homepage.univie.ac.at/robin.ristl/samplesize.php" ext-link-type="uri">https://homepage.univie.ac.at/robin.ristl/samplesize.php</ext-link>). For the tumor microarray, a priori analysis for allocation ratio of 9 tumor/non tumor indicated that a sample size of 94 or higher would detect a doubling of the H-score with 80% power and &#x003b1; = 0.05. For in vivo experiments, differences of 50% with 25% standard deviations in continuous endpoints of two independent groups of 0.7&#x02013;1 ratio would be detected for 4&#x02013;6 mice per group at 80&#x02013;90% power with &#x003b1; = 0.05.</p><p>Pearson&#x02019;s correlation and linear regression were used for normally distributed data. Differences among experimental groups were analyzed using a two-tailed t-test, Fisher&#x02019;s exact test, one-way or two-way ANOVA (with post-hoc tests). For non-normally distributed data, differences among experimental groups were analyzed using a two-tailed Mann&#x02013;Whitney U-test for unpaired samples, and correlations tested by Spearman&#x02019;s test. All tests were considered significant at P&#x02264;0.05. Unless otherwise specified, gene expression data are shown as boxplots with mean and range, and bars as mean and standard deviation (mean &#x000b1; SD. Prism 9 (GraphPad Software) was used for data analysis and graph preparation.</p></sec></sec><sec sec-type="results" id="sec014"><title>3. Results</title><sec id="sec015"><title>3.1 Expression of TfR1 in primary breast cancer</title><p>The transferrin receptor (TfR) is necessary for the survival of most cells; however, several reports have indicated that it is often substantially overexpressed in cancer [<xref rid="pone.0293700.ref019" ref-type="bibr">19</xref>&#x02013;<xref rid="pone.0293700.ref021" ref-type="bibr">21</xref>]. To investigate clinical and pathological association of TfR expression in breast cancer, we used data mining and immunohistochemistry on tissue microarrays (TMA).</p><p>Data on gene expression were obtained from the Gene Expression database for both normal and tumor tissue [<xref rid="pone.0293700.ref034" ref-type="bibr">34</xref>] (GENT2) combining GEO-deposited data from Affymetrix U133A or U133Plus2 arrays, and data from the cancer genome atlas (TCGA), which combines sequencing and microarray data from several platforms.</p><p>Both the GENT2 and TCGA breast cancer data sets showed increased gene expression of <italic toggle="yes">TFRC</italic> (p&#x0003c;0.0001) in breast cancer (N = 5574 and N = 1210) relative to normal breast (N = 475 and N = 113 respectively, <xref rid="pone.0293700.s002" ref-type="supplementary-material">S1A and S1B Fig</xref>).</p><p>To investigate associations with tumor staging, the samples from the TCGA dataset were stratified according to the parameters of the American Joint Committee on Cancer (AJCC) TNM (tumor, nodes, metastasis) system. No differences were found in the transcript levels of <italic toggle="yes">TFRC</italic> between T1, T2, T3, or T4 patients (P = 0.1), or according to N score (P = 0.4, ANOVA). Only 2.4% of patients in the TCGA dataset were metastatic at diagnosis, but no trend for differences in <italic toggle="yes">TFRC</italic> expression between M0 or M1 was noted (t-test, P&#x0003e;0.9). Accordingly, no differences were seen in <italic toggle="yes">TFRC</italic> RNA across stages I to IV (ANOVA, &#x003b1; = 0.05, 1-&#x003b2; = 0.21) (<xref rid="pone.0293700.s001" ref-type="supplementary-material">S1 Table</xref>).</p><p>The GENT2 dataset was stratified according to histological subtype, annotated for 1467 patients. Expression of <italic toggle="yes">TFRC</italic> was found in all subtypes, but with significant quantitative differences across types, with Luminal A type having lowest levels and TNBC the highest (P&#x0003c;0.001, &#x003b1; = 0.001, 1-&#x003b2;&#x02245;1). Stratification of the GENT2 dataset by grade also showed increase in <italic toggle="yes">TFRC</italic> gene expression across pathological grades (P&#x0003c;0.0001, 1-&#x003b2;&#x02245;1) [<xref rid="pone.0293700.ref021" ref-type="bibr">21</xref>].</p><p>Multivariate analysis of 1097 tumor samples in the TCGA dataset showed a significant correlation between <italic toggle="yes">TFRC</italic> and markers of proliferation, such as <italic toggle="yes">MKI67</italic> (Ki67), <italic toggle="yes">CCNB1</italic>, <italic toggle="yes">CCNA2</italic>, <italic toggle="yes">CDK2</italic>, <italic toggle="yes">CDK6</italic>, <italic toggle="yes">TOP2A</italic>, and <italic toggle="yes">TOP1</italic> (P&#x0003c;1E-20, r&#x0003e;0.3). Also, <italic toggle="yes">TFRC</italic> was negatively correlated with estrogen receptor <italic toggle="yes">ESR1</italic>. <italic toggle="yes">TFRC</italic> correlation was relatively weak with <italic toggle="yes">MYC</italic> (P = 0.003, r = 0.09), but highly significant with <italic toggle="yes">NRAS</italic> (P = 3.8E-21, r = 0.28) and <italic toggle="yes">KRAS</italic> (P = 3.2E-27, r = 0.32), recently associated with aggressive TNBC [<xref rid="pone.0293700.ref061" ref-type="bibr">61</xref>]. These results are in line with previous reports on <italic toggle="yes">TFRC</italic> expression being positively correlated with proliferation [<xref rid="pone.0293700.ref062" ref-type="bibr">62</xref>] and negatively with ER [<xref rid="pone.0293700.ref061" ref-type="bibr">61</xref>, <xref rid="pone.0293700.ref063" ref-type="bibr">63</xref>].</p><p>Protein expression of TfR in normal and malignant breast tissue was assessed by immunohistochemistry using a tissue microarray (TMA) of 107 human samples (99 breast cancer and 8 adjacent normal breast), stained for TfR with the FDA-approved anti-CD71 antibody MRQ-48, and scored taking as reference the darkest stain (highest expression) present within each tissue sample (<xref rid="pone.0293700.s002" ref-type="supplementary-material">S1D Fig</xref>). Unlike the continuum offered by transcriptomic analysis, IHC allowed to identify expression of TfR at significantly higher levels than background in 62/99 (62.6%) of breast cancer versus 2/8 (25%) of control breast tissue. This is consistent with previous reports showing by IHC expression in 70% of breast cancer biopsies [<xref rid="pone.0293700.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0293700.ref063" ref-type="bibr">63</xref>]. Semi-quantitative assessment showed that TfR expression was significantly increased in breast cancer compared to non-malignant adjacent breast tissue (average H-score 70&#x000b1;7; 8&#x000b1;5, P&#x0003c;0.05) (<xref rid="pone.0293700.g001" ref-type="fig">Fig 1D</xref>).</p><fig position="float" id="pone.0293700.g001"><object-id pub-id-type="doi">10.1371/journal.pone.0293700.g001</object-id><label>Fig 1</label><caption><title>Expression of TfR in primary breast tumors.</title><p>A-C) Gene expression of <italic toggle="yes">TFRC</italic> A) by stage (TGCA, total N = 1192), B) by histological subtype (GENT2, total N = 1467), C) by grade (GENT2, total N = 725). D-H) TfR immunohistochemistry (IHC) D) H-score of normal breast (outside of tumor margin, N = 8) versus malignant breast tumors (N = 99), E) representative images of breast cancer histological subtypes, F) H-score by subtype (total N = 98), G) H-score by stage (N = 99), H) H-score by grade (N = 91). *P&#x0003c;0.05 T-test, ***P&#x0003c;0.001, ****P&#x0003c;0.0001 one-way ANOVA-Tukey&#x02019;s post-hoc test.</p></caption><graphic xlink:href="pone.0293700.g001" position="float"/></fig><p>Next, breast cancer samples were stratified according to histological subtype, grade, and staging. TfR staining was detectable in 25/39 (64%) Luminal A, 12/17 (71%) Luminal B,10/19 (53%) HER2, and 10/23 (43%) TNBC. IHC intensity score showed high intra-group variability, but no noticeable trend across subtypes of breast cancer (P = 0.75, 1-&#x003b2; = 0.07).</p><p>Next, TMA biopsies were stratified according to the TNM system. TfR staining was observed in 5/6 (83%) T1 tumors, 41/66 (62%) T2, 5/9 (53%) T3, and 11/16 (69%) T4. Staining intensity was variable, but showed no significant inter-group differences (P = 0.5, 1-&#x003b2; = 0.8) (<xref rid="pone.0293700.s002" ref-type="supplementary-material">S1E Fig</xref>). The tumor H-score appeared higher in the 5 patients classified as N2 (138&#x000b1;43) relative to N0 (71&#x000b1;8), or N1 (52&#x000b1;15), likely due to unequal group composition and low statistical power (1-&#x003b2; = 0.54) (<xref rid="pone.0293700.s002" ref-type="supplementary-material">S1F Fig</xref>). Classification by stage showed consistent TfR expression, with no apparent difference in staining intensity between stage I (N = 5, H score 72&#x000b1;41), stage II (N = 73, 65&#x000b1;68), and stage III (N = 21, 81&#x000b1;80, P = 0.56, 1-&#x003b2; = 0.06, <xref rid="pone.0293700.g001" ref-type="fig">Fig 1G</xref>).</p><p>Analysis of the TMA by tumor grade showed TfR staining in all groups (<xref rid="pone.0293700.g001" ref-type="fig">Fig 1H</xref>), including grade 1 (N = 5, H score 103&#x000b1;29), grade 2 (N = 66, 70&#x000b1;80), and grade 3 (N = 20, 81&#x000b1;82), with no detectable differences in staining intensity (P = 0.38, 1-&#x003b2; = 0.13).</p><p>Overall, transcriptomic data, more quantitative and available for large number of cases, allowed to confirm previous reports of higher expression in more aggressive grades [<xref rid="pone.0293700.ref021" ref-type="bibr">21</xref>, <xref rid="pone.0293700.ref064" ref-type="bibr">64</xref>, <xref rid="pone.0293700.ref065" ref-type="bibr">65</xref>] and in TNBC [<xref rid="pone.0293700.ref021" ref-type="bibr">21</xref>, <xref rid="pone.0293700.ref063" ref-type="bibr">63</xref>&#x02013;<xref rid="pone.0293700.ref065" ref-type="bibr">65</xref>] (<xref rid="pone.0293700.g001" ref-type="fig">Fig 1B and 1C</xref>), and correlations with molecular markers of proliferation [<xref rid="pone.0293700.ref021" ref-type="bibr">21</xref>, <xref rid="pone.0293700.ref064" ref-type="bibr">64</xref>&#x02013;<xref rid="pone.0293700.ref066" ref-type="bibr">66</xref>] (<xref rid="pone.0293700.s002" ref-type="supplementary-material">S1C Fig</xref>). Immunohistochemistry showed high prevalence of TfR staining, with heterogeneity across tumors and even within the same tumor. Notably, high TfR protein expression could occur even in subtypes generally associated with lower transcript levels, such as ER+ or low-grade tumors. This suggests that the selection of cases eligible for TfR-targeted therapeutics should be based on the expression of TfR in the specific tumor, rather than on the histological subtype or grade.</p></sec><sec id="sec016"><title>3.2 Breast cancer expression of transferrin receptor after chemotherapy</title><p>Exposure to chemotherapy can induce profound changes in tumor cell metabolism and regulation of membrane receptors. To investigate the effects of pharmacological treatment on the expression of TfR, we used datamining, built a dedicated tumor microarray, and performed IHC on chemotherapy-treated patient-derived xenografts (PDX).</p><p>In the TCGA dataset, we found 53 samples annotated as having received additional chemotherapy, versus the other 1044 primary breast tumors. <italic toggle="yes">TFRC</italic> expression did not show differences between the two groups (P = 0.15), but unequal group composition and heterogeneity of therapeutic regimens may limit the statistical power and biological significance (1-&#x003b2; = 0.19) (<xref rid="pone.0293700.s003" ref-type="supplementary-material">S2A Fig</xref>).</p><p>We therefore searched Gene Exprexsion Omnibus (GEO) for transcriptomic data from breast cancer biopsies collected at diagnosis versus after treatment with neoadjuvant chemotherapy (NAC) or endocrine therapy (NAE) (<xref rid="pone.0293700.g002" ref-type="fig">Fig 2A</xref>). Positive controls for response to treatment were selected based on the literature. Effects of anthracyclines [<xref rid="pone.0293700.ref067" ref-type="bibr">67</xref>] or taxanes [<xref rid="pone.0293700.ref068" ref-type="bibr">68</xref>] would upregulate p21 (<italic toggle="yes">CDK1NA</italic>); aromatase inhibitors [<xref rid="pone.0293700.ref069" ref-type="bibr">69</xref>] and trastuzumab [<xref rid="pone.0293700.ref070" ref-type="bibr">70</xref>] would downregulate <italic toggle="yes">CCDN1</italic>.</p><fig position="float" id="pone.0293700.g002"><object-id pub-id-type="doi">10.1371/journal.pone.0293700.g002</object-id><label>Fig 2</label><caption><title>Expression of TfR after neoadjuvant therapy.</title><p>A) experimental design: unless otherwise specified pre- refers to tissue from the diagnostic biopsy, post- refers to tissue from the resected tumor; B) <italic toggle="yes">TFRC</italic> expression in GSE21974: 32 patients sampled before and after four cycles of epirubicin and cyclophosphamide prior to taxane (EC-T), C) <italic toggle="yes">TFRC</italic> expression in GSE18728 (N = 22 patients): biopsy samples collected at diagnosis (Pre) and after one cycle of capecitabine and docetaxel (NAC: Cy-TX), and from the resected tumor (Res); D) <italic toggle="yes">TFRC</italic> expression in GSE114082 (N = 17 patients) pre- and after trastuzumab (NAC:TR). E-G) Tumor microarray IHC TfR score E) waterfall plot of patient-matched ER+ breast cancer (BC) before and after NAC (N-14), F-G) H-score in (non-matched) samples from diagnostic punch biopsy (Pre, grey), resected tumors (Post-NAC, red), and regional lymph nodes (R-LN, teal) from F) ER+ patients (N = 38) and G) TNBC patients (N = 35. H) TfR IHC of PDX WHIM68, treated with paclitaxel (30mg/kg) and carboplatin (50mg/kg) (Carbotaxol) versus vehicle, and harvested after treatment and at relapse; treatment scheme, representative images of TfR staining and quantification scatter plot post-vehicle, post-NAC, and at relapse. *P&#x0003c;0.05 by paired T-test, **P&#x0003c;0.01 by ANOVA and Tukey&#x02019;s post-hoc test.</p></caption><graphic xlink:href="pone.0293700.g002" position="float"/></fig><p>In the GSE21974 dataset [<xref rid="pone.0293700.ref040" ref-type="bibr">40</xref>], profiling na&#x000ef;ve breast tumors versus treated with four cycles of epirubicin and cyclophosphamide, <italic toggle="yes">CDK1NA</italic> was increased in treated patients (P&#x0003c;0.01, <xref rid="pone.0293700.s003" ref-type="supplementary-material">S2B Fig</xref>). However, <italic toggle="yes">TFRC</italic> expression showed no difference (<xref rid="pone.0293700.g002" ref-type="fig">Fig 2B</xref>). The GSE18728 dataset [<xref rid="pone.0293700.ref041" ref-type="bibr">41</xref>] includes patients treated with capecitabine and docetaxel, sampled before (N = 21), after 1 cycle of NAC (N = 18), and at resection (N = 22). In this set, no significant changes were noted in <italic toggle="yes">TFRC</italic> expression between treated and untreated tumors (<xref rid="pone.0293700.g002" ref-type="fig">Fig 2C</xref>), unlike <italic toggle="yes">CDK1NA</italic> (P&#x0003c;0.05 <xref rid="pone.0293700.s003" ref-type="supplementary-material">S2C Fig</xref>). In the GSE28826 series [<xref rid="pone.0293700.ref071" ref-type="bibr">71</xref>], matched tumor samples were obtained before (N = 14) and after (N = 14) NAC with taxanes and anthracyclines. Again, sample size was adequate to show <italic toggle="yes">CDKN1A</italic> increase, but no differences were found in <italic toggle="yes">TFRC</italic> transcription (<xref rid="pone.0293700.s003" ref-type="supplementary-material">S2D and S2E Fig</xref>).</p><p>Effects of neoadjuvant endocrine therapy (NAE) were assessed on the dataset GSE153470 [<xref rid="pone.0293700.ref038" ref-type="bibr">38</xref>], profiling tumors from 81 post-menopausal women before and after treatment with aromatase inhibitors (AI). <italic toggle="yes">CCND1</italic> was significantly downregulated after AI (P&#x0003c;0.001, <xref rid="pone.0293700.s003" ref-type="supplementary-material">S2F Fig</xref>), but <italic toggle="yes">TFRC</italic> expression showed no difference between pre- and post-NAE samples (<xref rid="pone.0293700.s003" ref-type="supplementary-material">S2G Fig</xref>).</p><p>In GSE114082 [<xref rid="pone.0293700.ref039" ref-type="bibr">39</xref>], profiling 17 HER2+ tumors before and after treatment with trastuzumab, CCND1 was decreased as predicted for antibody inhibition of HER2 [<xref rid="pone.0293700.ref070" ref-type="bibr">70</xref>] (<xref rid="pone.0293700.s003" ref-type="supplementary-material">S2H Fig</xref>). Unlike other treatments, however, trastuzumab treated tumors also had a significant decrease in <italic toggle="yes">TFRC</italic> expression relative to baseline (<xref rid="pone.0293700.g002" ref-type="fig">Fig 2D</xref>). The dataset GSE130788, relative to the TRIO-B-07 clinical trial (NCT#00769470) [<xref rid="pone.0293700.ref045" ref-type="bibr">45</xref>], compared the gene expression profiles of HER2+ breast tumors (N = 199 samples) at baseline and after three trastuzumab-based NAC regimens (<xref rid="pone.0293700.s003" ref-type="supplementary-material">S2I Fig</xref>). In this more comprehensive multitherapy study, tumors sampled after treatment had significantly lower expression of <italic toggle="yes">TFRC</italic> (Two-way ANOVA, treatment P&#x0003c;0.0001, 1-&#x003b2;&#x02245;1). Decrease of expression of <italic toggle="yes">TFRC</italic> upon treatment with trastuzumab (alone or with chemotherapy) is consistent with the role of EGFR signaling in regulating iron homeostasis [<xref rid="pone.0293700.ref017" ref-type="bibr">17</xref>].</p><p>Overall, data mining shows that, with the exception of HER2 targeting, neoadjuvant chemotherapy does not negatively impact the expression of <italic toggle="yes">TFRC</italic>.</p><p>Custom-made tissue microarrays (TMA) were prepared from 72 de-identified biopsies from ER+ and 56 from TNBC patients (all comers, all treatment protocols), and stained for IHC of TfR.</p><p>For ER+ tumors, matching Pre- and Post-NAC (all protocols) biopsies were available and for 14 patients (<xref rid="pone.0293700.g002" ref-type="fig">Fig 2E</xref>), for TNBC 6 (<xref rid="pone.0293700.s003" ref-type="supplementary-material">S2I Fig</xref>). Comparison of matched pre- and post-NAC tumors showed a significant reduction in H-Score of TfR staining in ER+ (p&#x0003c;0.005, <xref rid="pone.0293700.g002" ref-type="fig">Fig 2E</xref>), and an average 30% reduction in TNBC (<xref rid="pone.0293700.s003" ref-type="supplementary-material">S2I Fig</xref>) that did not reach significance (N = 6, P = 0.09, 1-&#x003b2; = 0.33). However, 12/14 ER+ (85%, <xref rid="pone.0293700.g002" ref-type="fig">Fig 2E</xref>) and 6/6 TNBC (100%) were still positive for TfR staining.</p><p>The complete sets of ER+ (<xref rid="pone.0293700.g002" ref-type="fig">Fig 2F</xref>) and TNBC (<xref rid="pone.0293700.g002" ref-type="fig">Fig 2G</xref>) perioperative samples, not matched by patient, comprised na&#x000ef;ve tumors (N = 16 ER+ and N = 6 TNBC), NAC-treated tumors (N = 38 ER+ and N = 35 TNBC), and regional lymph nodes (N = 19 in ER+ and N = 15 TNBC). Na&#x000ef;ve tumors showed the highest H-scores in both ER+ (121&#x000b1;51) and TNBC (134&#x000b1;40) TMA. In comparison, lymph nodes showed significantly lower TfR staining, both in ER+(P = 004, 1-&#x003b2; = 0.77) and TNBC (P = 0.002, 1-&#x003b2; = 0.87). In the ER+ TMA, 16/16 (100%) of na&#x000ef;ve, 35/38 (87%), and 15/18 regional lymph nodes (83%) showed above-threshold TfR staining.</p><p>Patient derived xenograft (PDX) models offer the opportunity to study human tumors in vivo in highly controlled conditions. This allows the flexibility of an experimental model, for example matched vehicle/drug controls or the study of untreated relapse, while maintaining impressive similarity in drug sensitivity relative to the patients donating the tissue [<xref rid="pone.0293700.ref072" ref-type="bibr">72</xref>].</p><p>Here, we studied TfR expression in NSG mice inoculated with two TNBC PDX lines, WHIM68 (<xref rid="pone.0293700.g002" ref-type="fig">Fig 2H</xref>) and WHIM69 (<xref rid="pone.0293700.s004" ref-type="supplementary-material">S3 Fig</xref>), derived from the same patient respectively before and after NAC with docetaxel and carboplatin [<xref rid="pone.0293700.ref072" ref-type="bibr">72</xref>]. Mice with engrafted PDX tumors were treated with three cycles of carboplatin and paclitaxel (NAC) versus vehicle (Vh), and euthanized to collect tumors after treatment or upon relapse. Similar to previous reports [<xref rid="pone.0293700.ref008" ref-type="bibr">8</xref>], TfR staining was detectable in all PDX tumors at baseline. Moreover, both in WHIM68 and WHIM69 tumors, TfR expression was maintained after NAC, or at distant relapse, with low variability and high H-score (Figs <xref rid="pone.0293700.g002" ref-type="fig">2H</xref> and <xref rid="pone.0293700.s004" ref-type="supplementary-material">S3</xref>).</p><p>Overall, this data suggest that, albeit at variable levels, TfR is expressed in the majority of the breast cancer cells that remain after neoadjuvant chemotherapy.</p></sec><sec id="sec017"><title>3.3 Expression of transferrin receptor in human breast cancer metastases</title><p>Breast cancer metastases are responsible for the majority of breast cancer mortality and affect several organs, making their detection and systemic treatment a priority for biotechnological research. Bones are affected in 75% of metastatic cases (as only metastatic site in 40%), followed by lungs, lymph nodes, liver, and brain [<xref rid="pone.0293700.ref004" ref-type="bibr">4</xref>]. In order to evaluate expression of TfR by human breast cancer metastases, multi-organ and brain metastases datasets were analyzed, and a tissue microarray of matched bone metastases and primary breast tumors was generated.</p><p><italic toggle="yes">TFRC</italic> expression was analyzed in the GSE175692 dataset [<xref rid="pone.0293700.ref047" ref-type="bibr">47</xref>], comprising 184 samples of human breast cancer metastases, which showed consistent expression and no difference across 11 metastatic sites (<xref rid="pone.0293700.g003" ref-type="fig">Fig 3A</xref>). Similarly, in the GSE43837 dataset, <italic toggle="yes">TFRC</italic> was expressed at comparable levels between primary breast cancer and brain metastases (<xref rid="pone.0293700.g003" ref-type="fig">Fig 3B</xref>) [<xref rid="pone.0293700.ref048" ref-type="bibr">48</xref>].</p><fig position="float" id="pone.0293700.g003"><object-id pub-id-type="doi">10.1371/journal.pone.0293700.g003</object-id><label>Fig 3</label><caption><title>TfR expression in breast cancer metastases.</title><p>A) <italic toggle="yes">TFRC</italic> expression in GSE175692 biopsies from different metastatic sites (total N = 117), B) <italic toggle="yes">TFRC</italic> expression in GSE43837 of matched primary breast cancer and brain metastases samples (N = 18 patients). C-G) TMA TfR staining of primary breast cancer and bone metastases C) representative image, D) waterfall plot of 28 patient-matched primary tumor and bone metastasis samples (black breast, red bone); E-G) previous treatments at the time of metastasis in TMA samples: No Tx = no treatment, C = chemotherapy, C+E = chemotherapy and endocrine therapy, R = radiation therapy, R+C = radiation and chemotherapy, R+E = radiation and endocrine therapy, R+C+E = radio- chemio- and endocrine therapy, E) tumor subtypes vs treatments, LumA = luminal A, LumB = luminal B, HER2 = Her2-high, TNBC = triple negative breast cancer, cells: number, F) H-Score of bone metastases by treatment (tot N = 24). G) H-Score of bone metastases by histological subtype (tot N = 25).</p></caption><graphic xlink:href="pone.0293700.g003" position="float"/></fig><p>A dedicated TMA was prepared with matched primary breast cancers, sampled at diagnosis, and bone metastases from 24 patients (<xref rid="pone.0293700.g003" ref-type="fig">Fig 3C&#x02013;3E</xref>). Again, we found that 22/24 (92%) of primary breast cancers in this array expressed TfR. Also 20/24 (83%) of bone metastases expressed TfR (<xref rid="pone.0293700.g003" ref-type="fig">Fig 3C and 3D</xref>), with no correlation of the H-score relative to the original tumor (plot not shown). As expected, 21/24 patients had received systemic treatment prior to the appearance of metastases, but no association was found between type of treatment and TfR H-Score (<xref rid="pone.0293700.g003" ref-type="fig">Fig 3E</xref>). Staining for TfR was positive in 9/11 (81%) primary tumors and 8/11 (73%) bone metastases from Luminal A breast cancer. Both primary HER2+ tumors (2/2) were positive for TfR, but only the untreated patient showed TfR staining at the metastatic site. TfR staining was positive in both primary and bone biopsies from 4/4 Luminal B and 6/6 TNBC patients. Semi-quantitative assessment of staining intensity showed no significant inter-group differences (ANOVA 1-&#x003b2; = 0.28).</p><p>These findings confirm that, similar to primary tumors, most breast cancer metastases express high levels of transferrin receptors, though at variable levels.</p></sec><sec id="sec018"><title>3.4 Expression of transferrin receptor in mouse models of breast cancer metastases</title><p>In order to establish whether syngeneic mouse models of metastatic breast cancer replicate the variable pattern of expression of TfR, murine breast cancer models were investigated by datamining and histology.</p><p>In GSE165393, RNAseq identified <italic toggle="yes">tfrc</italic> transcripts in all MMTV-PyMT tumor sites (<xref rid="pone.0293700.s004" ref-type="supplementary-material">S3B Fig</xref>), and GSE62598 [<xref rid="pone.0293700.ref073" ref-type="bibr">73</xref>] in all 4T1 tumors or metastases (<xref rid="pone.0293700.s004" ref-type="supplementary-material">S3C Fig</xref>). Neither dataset had statistical power to test inter-group differences (1-&#x003b2; = 0.2 and 1-&#x003b2; = 0.3), but both showed variability in expression within and between groups.</p><p>To evaluate TfR by IHC, a TMA was prepared with samples of mammary fat pad (MFP) tumors and metastases from mice inoculated with the Bo1 luminal B breast cancer cell line [<xref rid="pone.0293700.ref058" ref-type="bibr">58</xref>] (<xref rid="pone.0293700.s004" ref-type="supplementary-material">S3D Fig</xref>), or the 4T1 TNBC (<xref rid="pone.0293700.s004" ref-type="supplementary-material">S3E and S3F Fig</xref>). TfR expression was detectable in all cancer tissues, particularly in Bo1 metastases (<xref rid="pone.0293700.s004" ref-type="supplementary-material">S3D Fig</xref>), with large variability between samples and groups.</p><p>Overall, mouse models of breast cancer mirrored the prevalence and variability of TfR expression at metastatic sites that is observed in humans.</p></sec><sec id="sec019"><title>3.5 Uptake of transferrin in murine model of triple negative breast cancer metastases</title><p>Previous studies on the use of transferrin conjugates in breast cancer considered primary breast tumors [<xref rid="pone.0293700.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0293700.ref024" ref-type="bibr">24</xref>]. Here, we set out to study the distribution of transferrin conjugates to breast cancer metastases, utilizing commercially available fluorescent transferrin consisting of stable conjugates of recombinant transferrin to AlexaFluor-750 (AF750-Tf) or AlexaFluor-680 (AF680-Tf).</p><p>In order to establish the background accumulation of AF750-Tf and its relationship with expression of its receptors, we compared imaging of non-tumor mice and data on gene expression. Female C57Bl/6 mice were injected with transferrin-750 (AF750-Tf) or vehicle (PBS), and underwent serial in vivo optical imaging (IVIS, Perkin Elmer). In AF750-Tf injected mice,at 6 and 24h hours high fluorescence was recorded the regions corresponding to the liverand in the urinary bladder in vivo (<xref rid="pone.0293700.s005" ref-type="supplementary-material">S4A Fig</xref>). Ex-vivo imaging showed accumulation of AF750-Tf primarily in the liver, though significant fluorescence was also detected in several organs, such as lungs and kidneys (<xref rid="pone.0293700.s005" ref-type="supplementary-material">S4A Fig</xref>). Baseline tissue expression of <italic toggle="yes">tfrc</italic> and <italic toggle="yes">tfr2</italic> in mice was obtained from three datasets from the Gene Expression Atlas (<ext-link xlink:href="https://www.ebi.ac.uk/gxa" ext-link-type="uri">https://www.ebi.ac.uk/gxa</ext-link>, <xref rid="pone.0293700.s005" ref-type="supplementary-material">S4C-S4E Fig</xref>). The average sum of <italic toggle="yes">Tfrc</italic> and <italic toggle="yes">Tfr2</italic> TPM for each organ was then compared to the average radiant efficiency measured ex vivo after injection of AF750-Tf. Despite the use of multiple and independent data sets for both variables, we found a strong positive correlation (p = 0.0005, r = 0.85) between uptake of AF750-Tf and gene expression of its receptors in the same tissue (<xref rid="pone.0293700.g004" ref-type="fig">Fig 4A</xref>). Hence, in our system physiologically high expression of TfR and TfR2 can determine high uptake of Tf-conjugates at the organ level, translating into high background for the detection of tumor lesions.</p><fig position="float" id="pone.0293700.g004"><object-id pub-id-type="doi">10.1371/journal.pone.0293700.g004</object-id><label>Fig 4</label><caption><title>Biodistribution of AF680-Tf in 4T1 metastatic model versus non-tumor Balb/c mice.</title><p>A) In vivo imaging over time relative to injection of AF680 in one non-tumor (top) and two tumor bearing mice (bottom), left: BLI at t = 24h tumor sites, right: PerL imaging, B) ex-vivo PerL imaging for AF680 of lungs, kidneys (K), liver, and spleen (Sp) of normal (left) versus 4T1 tumor-bearing mice (right); C-D) AF680-Tf fluorescence intensity (F.I.) in arbitrary units (A.U.) of group 1 organs of non tumor (grey, NoT) versus tumor (red, 4T1) mice at C) 6h from injection (N = 4 non tumor and N = 5 tumor) and D) 24h from injection (N = 3 non tumor, N = 4 tumor); E) representative ex-vivo BLI (top) and AT680-Tf imaging (bottom) of hindlimb bones (Leg) and spine of one non-tumor (left) and two 4T1 tumor bearing mice (right); F-G) AF680-Tf fluorescence intensity (F.I.) in arbitrary units (A.U.) of bones of non tumor (grey, NoT) versus tumor (red, 4T1) mice at F) 6h from injection (N = 4 non tumor and N = 5 tumor) and G) 24h from injection (N = 3 non tumor, N = 4 tumor). **P&#x0003c;0.01 by two-way ANOVA and &#x00160;id&#x000e1;k test.</p></caption><graphic xlink:href="pone.0293700.g004" position="float"/></fig><p>The metastatic triple negative breast cancer model 4T1 was then compared to healthy BALB/cj controls. Uptake of persistent luminescence (PerL) conjugates of transferrin was evaluated 12 days after cardiac injection, in vivo (<xref rid="pone.0293700.g004" ref-type="fig">Fig 4A</xref>) and ex vivo (<xref rid="pone.0293700.g004" ref-type="fig">Fig 4B&#x02013;4F</xref>) [<xref rid="pone.0293700.ref074" ref-type="bibr">74</xref>]. Systemic tumor engraftment was verified by total-body BLI (Figs <xref rid="pone.0293700.g004" ref-type="fig">4A</xref> and <xref rid="pone.0293700.s005" ref-type="supplementary-material">S4F</xref>). In both 4T1 tumor and non tumor-bearing mice, serial in vivo 700nm LiCor Perl scans showed high fluorescence in the area of the liver and bladder (<xref rid="pone.0293700.g004" ref-type="fig">Fig 4A</xref>), consistent with previous results (<xref rid="pone.0293700.s005" ref-type="supplementary-material">S4A Fig</xref>) and published work [<xref rid="pone.0293700.ref075" ref-type="bibr">75</xref>]. Based pharmacokinetics (not shown), one cohort of mice was sacrificed 6h after AF680-Tf injection, and one after 24h. Ex. vivo optical imaging showed broad distribution of labeled transferrin, with high levels in lungs, liver, and kidneys, for both non-tumor and tumor mice. At these sites, fluorescence intensity in 4T1 and non tumor-bearing mice was no higher than in control organs (<xref rid="pone.0293700.g004" ref-type="fig">Fig 4B&#x02013;4D</xref>) in either the 6h (<xref rid="pone.0293700.g004" ref-type="fig">Fig 4C</xref>) or 24h (<xref rid="pone.0293700.g004" ref-type="fig">Fig 4D</xref>) groups, even when BLI showed significant tumor burden (<xref rid="pone.0293700.s005" ref-type="supplementary-material">S4G-S4H Fig</xref>). Uptake of AF680-Tf was significantly increased in the vertebrae of tumor bearing mice (<xref rid="pone.0293700.g004" ref-type="fig">Fig 4E&#x02013;4G</xref>), both in the 6h (P&#x0003c;0.001) and 24h (P&#x0003c;0.01) groups, consistent with bone metastases (<xref rid="pone.0293700.g004" ref-type="fig">Fig 4E</xref>) detected by BLI. In the leg bones, where BLI showed a more variable and less discrete pattern of metastatic growth, fluorescence intensity was non-superior to non-tumor controls.</p><p>Overall, we found that at metastatic sites the uptake of labeled transferrin may be variable, and that high physiological expression of TfR and TfR2 by target organs can affect the ability of Tf-conjugates to identify tumor sites, particularly for smaller lesions.</p></sec><sec id="sec020"><title>3.6 Extracellular iron regulates uptake of transferrin by breast cancer cells in vitro</title><p>Molecular targeting depends on the availability of homing receptors. In the 3&#x02019;UTR of <italic toggle="yes">TFRC</italic>, an iron responsive element (IRE) allows fine control of its expression. Previous work showed that breast cancer cells downregulate TfR when iron is overabundant, and overexpress it upon iron chelation [<xref rid="pone.0293700.ref076" ref-type="bibr">76</xref>, <xref rid="pone.0293700.ref077" ref-type="bibr">77</xref>]. We therefore asked whether this mechanism translates to uptake of transferrin conjugates, and whether treatment with FDA-approved iron chelator deferoxamine (DFO) could be used to improve targeting through TfR.</p><p>MCF-7 intraductal breast cancer cells were treated for 24h with ammonium citrate (FAC), deferoxamine (DFO), or vehicle, then incubated with AF488-Tf for 30 minutes. Live optical microscopy showed some cytoplasmic staining in control cells, little to no staining in FAC-treated cells, and enhanced cytoplasmic and membrane staining in DFO-treated cells (<xref rid="pone.0293700.g005" ref-type="fig">Fig 5A</xref>).</p><fig position="float" id="pone.0293700.g005"><object-id pub-id-type="doi">10.1371/journal.pone.0293700.g005</object-id><label>Fig 5</label><caption><title>Non-toxic iron chelation upregulates transferrin uptake in breast cancer cells <italic toggle="yes">in vitro</italic> but does not affect tumor growth <italic toggle="yes">in vivo</italic>.</title><p>A-D) <italic toggle="yes">In vitro</italic> uptake of transferrin conjugates in breast cancer cells A) live imaging of Phrodo Red transferrin conjugate uptake MDA-MB-231 treated with vehicle (left) or DFO 200&#x003bc;M for 48h (right); B) uptake of Tf by fluorimetry of MDA-MB-231 cells pre-treated with FAC 200&#x003bc;M, or DFO 200&#x003bc;M for 48h, ex485/em515nm fluorescence divided by 570 nm optical density after nuclear staining with crystal violet (CV), C) T47D cells pre-treated with FAC 200&#x003bc;M, or DFO 200&#x003bc;M for 24h, ratio of fluorescence intensity at ex485/em515 nm (AF488-Tf) and Hoechst (ex350/em461 nm). D) AF488-Tf uptake by Bo1 cells treated with 100 &#x003bc;M DFO or FAC vs vehicle (AF488-Tf/CV as above); No Tf: background control of cells not exposed to fluorescent transferrin; *P&#x0003c;0.05, ***P&#x0003c;0.001, ****P&#x0003c;0.0001, ns non significant; one-way ANOVA and Tukey&#x02019;s post-hoc test. E-F) Effect of treatment with DFO in vivo on serum ferritin in mice, E) treatment diagram: non-tumor bearing mice (N = 5) were injected i.m. six times over 11 days with vehicle (HBSS), DFO 100mg/kg, or DFO 200mg/kg, and i.v. AF750-Tf on day 11, then sacrificed at day 12 F) serum ferritin ELISA at day 12, black dashed line: normal range, red dashed line: abnormal or pharmacologically lowered ferritin. G, H) Effect of DFO treatment on tumor growth in the metastatic Bo1 model G) treatment diagram: mice were inoculated by left ventricle injection, then imaged by BLI to establish tumor engraftment at day 4 and growth at day 8 and 11, treated with 4 injections of DFO 200mg/kg over 5 days, and intravenous AF750-Tf on day 10, H) total-body BLI at 4, 8, and 11 days after intracardiac inoculation of Bo1, average radiance in p/s/cm<sup>2</sup>/sr (N = 5/group).</p></caption><graphic xlink:href="pone.0293700.g005" position="float"/></fig><p>To verify intracellular delivery, TNBC MDA-MB-231 cells were treated with DFO or vehicle then incubated with the pH-sensitive pHrodo&#x02122; Red transferrin, which becomes brightly fluorescent in the acidic environment of the endosome. Live microscopy showed diffuse and punctate intracellular fluorescence after tracer incubation, with higher intensity in DFO-treated cells (<xref rid="pone.0293700.g005" ref-type="fig">Fig 5B</xref>).</p><p>Microplate fluorimetry further showed that uptake of AF488-Tf in MDA-MB-231 was decreased by 2/3 upon FAC supplementation (P&#x0003c;0.001) and increased by 2/3 in cells pre-treated with DFO (P&#x0003c;0.05, <xref rid="pone.0293700.g005" ref-type="fig">Fig 5C</xref>). Luminal A breast cancer cells T47D showed no decrease in uptake of AF488-Tf upon iron supplementation (FAC 100-200&#x003bc;M, +1% to -23%). However, DFO increased transferrin uptake by 40% (P&#x0003c;0.01) at 80 &#x003bc;M DFO (not shown), by 75% at 100&#x003bc;M (P&#x0003c;0.01, not shown), and doubled it at 200 &#x003bc;M (P&#x0003c;0.0001, <xref rid="pone.0293700.g005" ref-type="fig">Fig 5D</xref>). In murine luminal B cells Bo1, treatment with FAC for 48h did not decrease uptake of AF488-Tf, but 200 &#x003bc;M DFO increased transferrin uptake by 130% (P&#x0003c;0.001, <xref rid="pone.0293700.g005" ref-type="fig">Fig 5E</xref>).</p><p>These results demonstrate that iron chelation can enhance uptake of transferrin by breast cancer cells.</p></sec><sec id="sec021"><title>3.7 Short-term iron chelation in the C57Bl/6 breast cancer metastasis Bo1 model</title><p>In order to translate the use of DFO to improve delivery of transferrin conjugates to breast cancer in vivo, two potential limitations needed to be addressed: safety of the treatment, and effects on tumor growth that may add confounding factors.</p><p>Tolerability of DFO in combination with labeled transferrin was tested in non-tumor bearing mice, receiving six intraperitoneal injections of DFO 100mg/kg or 200mg/kg over 11 days, then one intravenous injection of Tf-750 (<xref rid="pone.0293700.g005" ref-type="fig">Fig 5E</xref>). No behavioral changes, alterations in fur or posture, or macroscopic anomalies at necropsy were noted for either dose of DFO. Further, body weight remained stable (<xref rid="pone.0293700.s006" ref-type="supplementary-material">S5D Fig</xref>).</p><p>In order to test whether chelation had caused iron deficiency, we measured ferritin levels in the serum by ELISA. Long-term DFO treatment was previously reported to induce 20&#x02013;30% decrease in serum ferritin in mice [<xref rid="pone.0293700.ref078" ref-type="bibr">78</xref>, <xref rid="pone.0293700.ref079" ref-type="bibr">79</xref>]. However, all of our mice showed ferritinemia in the range reported for age- and strain- matched healthy mice [<xref rid="pone.0293700.ref080" ref-type="bibr">80</xref>], with no differences between treatments (<xref rid="pone.0293700.g005" ref-type="fig">Fig 5F</xref>).</p><p>DFO was previously reported to decrease growth of breast cancer in vitro and in primary tumors [<xref rid="pone.0293700.ref081" ref-type="bibr">81</xref>, <xref rid="pone.0293700.ref082" ref-type="bibr">82</xref>]. To determine whether DFO treatment would affect the growth in the luminal B metastasis model, 6 week old C57Bl/6 were injected with Bo1 breast cancer cells in the left ventricle, imaged for engraftment on day 4, treated, and serially imaged by BLI (IVIS)(<xref rid="pone.0293700.g005" ref-type="fig">Fig 5G</xref>). DFO (200mg/kg i.p., N = 5) or vehicle (HBSS, N = 5) were administered on days 7, 8, 10 and 11. No weight loss (<xref rid="pone.0293700.s006" ref-type="supplementary-material">S5D Fig</xref>) or macroscopic signs of toxicity were observed in any of the groups. Serial ventral total body BLI showed constant increase of luminescence, with no differences in tumor growth between vehicle- and DFO-treated mice (<xref rid="pone.0293700.g005" ref-type="fig">Fig 5H</xref>).</p></sec><sec id="sec022"><title>3.8 Iron chelation improves the localization of fluorescently labeled transferrin to tumor sites in the Bo1 metastatic luminal B breast cancer model</title><p>Having established a high-load disseminated tumor burden in Bo1-injected mice with no interference from treatment (<xref rid="pone.0293700.g005" ref-type="fig">Fig 5F&#x02013;5H</xref>), dual in vivo imaging was performed on day 11, 24h after injection of AF750-Tf (<xref rid="pone.0293700.g006" ref-type="fig">Fig 6A</xref>). Luciferase activity was evident in multiple sites in tumor-bearing mice. Fluorescence imaging showed accumulation of AF750 in the liver (as previously, <xref rid="pone.0293700.g004" ref-type="fig">Fig 4</xref>) and at several foci throughout the body.</p><fig position="float" id="pone.0293700.g006"><object-id pub-id-type="doi">10.1371/journal.pone.0293700.g006</object-id><label>Fig 6</label><caption><title>Iron chelation in metastatic Bo1 enhances the uptake of transferrin (AF750) at tumor sites.</title><p>A-B) In vivo imaging with BLI and AF750 A) representative images of two tumor-bearing mice treated with vehicle (left) and two with 4 i.p. injections of DFO 200mg/kg (right), by BLI (top, rainbow pseudocolor of average radiance) and 750 nm epifluorescence (bottom, blue-hot psuedocolor of average radiant efficiency), red arrows: tumor lesions seen by BLI but not AF750, geen arrows: tumor sites where BLI and AF750-Tf co-localize, B) percentage of tumor foci by BLI that did (yellow) or did not (purple) show AF750-Tf accumulation in mice treated with vehicle versus DFO, P&#x0003c;0.0001 by Fisher&#x02019;s exact test. C-J) ex-vivo imaging by BLI and AF750, representative images of BLI (top) and 750nm epifluorescence (bottom) (C, G, H), correlation between BLI and AF750 (E,F, I, J), bar graphs (G,K), C) example of group 1 organs ex-vivo imaging in vehicle (top) and DFO&#x02014;treated (bottom) mice; D) representative image of adrenal glands, mesenter (fat, vessels, and lymph nodes), ovarian omentum, ovaries, uterus and tubae in vehicle (left) and DFO -treated (right) mice; E-F) correlation between tumor burden and AF750-accumulation in ROI from group 2: X axis, Log-transformed average radiance (photons/s/cm<sup>2</sup>/sr), Y axis, Log-transformed average radiant efficiency ((photons/s/cm<sup>2</sup>/sr)/(&#x003bc;W/cm<sup>2</sup>) E) vehicle-treated mice and F) DFO-treated mice; G) comparison of AF750-Tf uptake in the legs and spines of non tumor-bearing (N = 3, grey bars, No Tumor), Bo1 mice injected with vehicle (N = 5, teal), and Bo1 mice treated with DFO (N = 5, red); **P&#x0003c;0.01, ****P&#x0003c;0.0001 by two-way ANOVA and &#x00160;id&#x000e1;k test; H) representative images of spines from two vehicle-treated (left) and two DFO-treated (right) BO1 mice I-J) correlation between tumor burden and accumulation of Tf in the bones (pelvis, legs, spine) of I) vehicle-treated (P = 0.0074, Pearson&#x02019;s r = 0.522, R = 0.272) and J) DFO-treated (P&#x0003c;0.0001, r = 0.769, R = 0.591); K) percentage of tumor foci by ex-vivo BLI that did (yellow) or did not (purple) show AF750-Tf accumulation in mice treated with vehicle versus DFO, P = 0.006 by Fisher&#x02019;s exact test.</p></caption><graphic xlink:href="pone.0293700.g006" position="float"/></fig><p>To evaluate whether DFO had improved uptake of AF750-Tf, BLI and epifluorescence sequences were compared, counting the number of foci that were caught in both modalities versus only by BLI (<xref rid="pone.0293700.g006" ref-type="fig">Fig 6B</xref>). DFO-treated mice had a significantly higher percentage of metastatic foci accumulating AF750-Tf (84% &#x000b1; 28% vs 52%&#x000b1;2.8%, Fisher&#x02019;s test P&#x0003c;0.0001).</p><p>Dual ex-vivo imaging demonstrated broad tumor involvement of several organs and tissues, consistent with lymph node, peritoneal, bone, and organ metastases. To investigate the ability of transferrin conjugates to target metastases, we investigated the qualitative and semi-quantitative association between regions of high intensity of epifluorescence and BLI, and correlated the radiance and radiant efficiency for epifluorescence in fixed-shape ROI as previously described [<xref rid="pone.0293700.ref027" ref-type="bibr">27</xref>]. Based on previous experiments on Tf uptake in non-tumor mice (Figs <xref rid="pone.0293700.g004" ref-type="fig">4</xref> and <xref rid="pone.0293700.s005" ref-type="supplementary-material">S4</xref>), target tissues and organs were divided into three groups: high background (group 1, <xref rid="pone.0293700.g006" ref-type="fig">Fig 6C</xref>), soft tissue sites of metastases (group 2, <xref rid="pone.0293700.g006" ref-type="fig">Fig 6D</xref>), and bones (group 3).</p><p>Organs in group 1 had high fluorescence in all mice, consistent with high physiological uptake or involvement in clearance of AF750-Tf, with no difference between groups (Figs <xref rid="pone.0293700.g006" ref-type="fig">6C</xref> and <xref rid="pone.0293700.s007" ref-type="supplementary-material">S6A</xref> ). Occasional redistribution of fluorescent signal within the organ towards tumor-affected areas, could be observed in the lungs (<xref rid="pone.0293700.g006" ref-type="fig">Fig 6C</xref> arrow, <xref rid="pone.0293700.s007" ref-type="supplementary-material">S6B Fig</xref>). However, overall no correlation was found between fluorescence and luminescence in either vehicle- or DFO-treated mice (<xref rid="pone.0293700.s007" ref-type="supplementary-material">S6C and S6D Fig</xref>).</p><p>Group 2 included organs with lower background where most metastatic foci were visible, namely mesentery, ovaries, uterus and fallopian tubes, ovarian omentum, and adrenal glands (<xref rid="pone.0293700.g006" ref-type="fig">Fig 6D</xref>). Vehicle-treated mice showed some correlation between BLI and epifluorescence in this group of organs (P&#x0003c;0.05, r = 0.42, <xref rid="pone.0293700.g006" ref-type="fig">Fig 6E</xref>). In DFO-treated mice, however, the correlation between tumor load and AF750-Tf uptake was significantly improved (P&#x0003c;0.001, r = 0.66, <xref rid="pone.0293700.g006" ref-type="fig">Fig 6F</xref>).</p><p>Similar to the 4T1/BalbC model, vertebral metastases increased AF750-Tf uptake relative to non-tumor mice in the spine of both vehicle- and DFO- treated Bo1 d11 mice (<xref rid="pone.0293700.g006" ref-type="fig">Fig 6F and 6G</xref>, P&#x0003c;0.001 <xref rid="pone.0293700.s007" ref-type="supplementary-material">S6E Fig</xref>). Bone metastases to the hindlimbs and pelvis in this cohort were generally small, and total radiant efficiency was non superior to non-tumor controls, similarly to what observed in 4T1 mice. However, we found a positive correlation between luciferase activity and AT750-Tf uptake in vehicle-treated mice (P&#x0003c;0.01, r = 52, <xref rid="pone.0293700.g006" ref-type="fig">Fig 6H</xref>) and a very strong correlation mice treated with DFO (p&#x0003c;0.0001, r = 0.77, <xref rid="pone.0293700.g006" ref-type="fig">Fig 6I</xref>).</p><p>Ultimately aiming at assessing whether transferrin conjugates would target a metastatic focus, we counted the tumor foci as seen by ex-vivo BLI that also showed AF750-Tf accumulation. Vehicle-treated mice showed AF750-Tf signal on average in 64.6% (SD 18.7%) of BLI-positive foci, while DFO-treated mice had detectable uptake of TF750 in 83.2% of ROI (SD 13.2%). Contingency analysis by Fisher&#x02019;s exact tests suggested a significant difference in favor of DFO-treated mice (P = 0.015, <xref rid="pone.0293700.g006" ref-type="fig">Fig 6E</xref>).</p><p>Having observed that Tf-conjugated fluorophores were hardest to trace in smaller tumor lesions (Figs <xref rid="pone.0293700.g004" ref-type="fig">4</xref> and <xref rid="pone.0293700.g006" ref-type="fig">6</xref>), we set out to test the effects of DFO at an earlier stage of the diffuse Bo1 tumor model, characterized by significantly lower tumor burden.</p><p>Female C57Bl/6 mice were injected Bo1 cells in the left ventricle, and BLI was performed on day 3 to establish tumor engraftment before treatment (<xref rid="pone.0293700.g007" ref-type="fig">Fig 7A</xref>). Mice received daily i.p. injections from day 3 to day 5 with DFO 200mg/kg or HBSS (vehicle), then intravenous AF750-Tf on day 6, with no weight loss or signs of toxicity (<xref rid="pone.0293700.s008" ref-type="supplementary-material">S7B Fig</xref>). Serial imaging with BLI to monitor tumor growth showed no difference between DFO-treated and untreated mice (Figs <xref rid="pone.0293700.g007" ref-type="fig">7B</xref> and <xref rid="pone.0293700.s008" ref-type="supplementary-material">S7A</xref>), despite the high dose and early treatment initiation.</p><fig position="float" id="pone.0293700.g007"><object-id pub-id-type="doi">10.1371/journal.pone.0293700.g007</object-id><label>Fig 7</label><caption><title>Iron chelation enhances the uptake of transferrin (AF750) in low-tumor burden Bo1 model.</title><p>A) Experimental design: mice were inoculated with Bo1 i.c. and treated from day 3 imaged with vehicle (V) or DFO; injection of AF750-Tf on day6 and imaging day 7; B) quantification of total-body radiance over time show no difference in tumor bearing mice treated with vehicle or DFO, *** P&#x0003c;0.001 in non tumor-bearing controls C) ex-vivo imaging of bones from one vehicle and one DFO-treated mice by BLI (top) and AF750-tf epifluorescence (bottom), D-E) Correlation between BLI and AF750-Tf fluorescence in the bones (legs, pelvis, spine) of D) vehicle-treated mice (P = 0.069, r = 0.42, R = 0.17, N = 5) and E) DFO-treated (P&#x0003c;0.0001, r = 0.66, R = 0.43, N = 5) mice.</p></caption><graphic xlink:href="pone.0293700.g007" position="float"/></fig><p>Ex vivo BLI showed few and small metastases at several sites. In visceral organs and soft tissues, no correlation between BLI and AF750-Tf fluorescence was found in vehicle- (P = 0.108, r = 0.277, R = 0.077, <xref rid="pone.0293700.s008" ref-type="supplementary-material">S7C Fig</xref>) nor DFO-treated animals (P = 0.067, r = 0.250, R = 0.064, <xref rid="pone.0293700.s008" ref-type="supplementary-material">S7D Fig</xref>). In the leg bones and spine few and small metastatic foci could be identified by BLI (<xref rid="pone.0293700.g007" ref-type="fig">Fig 7C</xref>) independent of treatment. In vehicle-treated mice, unlike in the late-stage experiment, no significant correlation was found between BLI and (P = 0.069, r = 0.42, R = 0.17) (<xref rid="pone.0293700.g007" ref-type="fig">Fig 7C</xref>). By contrast, in DFO-treated mice BLI radiance and epifluorescence from AF750-Tf were strongly correlated (p&#x0003c;0.0001. r = 0.66, R = 0.43).</p><p>Overall, this data provides proof-of-principle that systemic iron chelation can increase Tf uptake in breast cancer metastases.</p></sec></sec><sec sec-type="conclusions" id="sec023"><title>4. Discussion</title><p>In this study, we set out to characterize gene and protein expression of transferrin receptor (TfR, <italic toggle="yes">TFRC</italic>) of breast cancer broadly and systematically. TfR was expressed in breast cancer, including untreated tumors, residual tumor tissue after neoadjuvant chemotherapy, and metastases. Preclinical models showed variable uptake of fluorescently-labeled transferrin at metastatic sites. Treatment with DFO [<xref rid="pone.0293700.ref030" ref-type="bibr">30</xref>, <xref rid="pone.0293700.ref076" ref-type="bibr">76</xref>] increased the uptake of transferrin conjugates by breast cancer cells in vitro and in a mouse model of metastatic breast cancer.</p><p>Iron is essential to cellular metabolism, growth, and signaling [<xref rid="pone.0293700.ref082" ref-type="bibr">82</xref>, <xref rid="pone.0293700.ref083" ref-type="bibr">83</xref>], and its uptake depends on transferrin receptors, primarily TfR (<italic toggle="yes">TFRC</italic>) [<xref rid="pone.0293700.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0293700.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0293700.ref084" ref-type="bibr">84</xref>]. TfR is present in all cells, but cancer cells overexpress it in order to increase iron uptake and sustain higher metabolism and proliferation [<xref rid="pone.0293700.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0293700.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0293700.ref019" ref-type="bibr">19</xref>&#x02013;<xref rid="pone.0293700.ref022" ref-type="bibr">22</xref>] (<xref rid="pone.0293700.s001" ref-type="supplementary-material">S1 Table</xref> and Figs <xref rid="pone.0293700.g001" ref-type="fig">1D</xref> and <xref rid="pone.0293700.s002" ref-type="supplementary-material">S1A and S1B</xref>). Because of this, many groups have developed diagnostic and therapeutic agents by binding to transferrin drugs or imaging agents to target cancer cells [<xref rid="pone.0293700.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0293700.ref007" ref-type="bibr">7</xref>&#x02013;<xref rid="pone.0293700.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0293700.ref022" ref-type="bibr">22</xref>, <xref rid="pone.0293700.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0293700.ref025" ref-type="bibr">25</xref>, <xref rid="pone.0293700.ref026" ref-type="bibr">26</xref>, <xref rid="pone.0293700.ref028" ref-type="bibr">28</xref>, <xref rid="pone.0293700.ref083" ref-type="bibr">83</xref>, <xref rid="pone.0293700.ref085" ref-type="bibr">85</xref>&#x02013;<xref rid="pone.0293700.ref087" ref-type="bibr">87</xref>].</p><p>In breast cancer, biomaterials targeting transferrin receptor were tested in primary orthotopic tumors [<xref rid="pone.0293700.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0293700.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0293700.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0293700.ref025" ref-type="bibr">25</xref>&#x02013;<xref rid="pone.0293700.ref028" ref-type="bibr">28</xref>, <xref rid="pone.0293700.ref086" ref-type="bibr">86</xref>, <xref rid="pone.0293700.ref087" ref-type="bibr">87</xref>], where a 70% average prevalence of TfR expression is well established [<xref rid="pone.0293700.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0293700.ref021" ref-type="bibr">21</xref>, <xref rid="pone.0293700.ref063" ref-type="bibr">63</xref>]. For primary breast cancer, however, effective treatments are available. Innovative therapies are needed for metastatic or previously treated cancers, which respond poorly to chemotherapy but are underrepresented in preclinical research. Our study therefore started by analyzing expression of TfR in all breast cancers, including post-chemotheraphy and metastatic tissue.</p><p>High <italic toggle="yes">TFRC</italic> expression was confirmed (Figs <xref rid="pone.0293700.g001" ref-type="fig">1</xref> and <xref rid="pone.0293700.s002" ref-type="supplementary-material">S1A and S1B</xref>), particularly in cases with high pathological grade [<xref rid="pone.0293700.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0293700.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0293700.ref021" ref-type="bibr">21</xref>, <xref rid="pone.0293700.ref062" ref-type="bibr">62</xref>] (<xref rid="pone.0293700.g001" ref-type="fig">Fig 1C</xref>) and of triple negative subtype [<xref rid="pone.0293700.ref021" ref-type="bibr">21</xref>, <xref rid="pone.0293700.ref062" ref-type="bibr">62</xref>, <xref rid="pone.0293700.ref064" ref-type="bibr">64</xref>, <xref rid="pone.0293700.ref065" ref-type="bibr">65</xref>, <xref rid="pone.0293700.ref086" ref-type="bibr">86</xref>] [<xref rid="pone.0293700.ref088" ref-type="bibr">88</xref>] (<xref rid="pone.0293700.g001" ref-type="fig">Fig 1B</xref>). In line with the reported association with Ki67 (<italic toggle="yes">MKI67</italic>, <xref rid="pone.0293700.s002" ref-type="supplementary-material">S1C Fig</xref>) [<xref rid="pone.0293700.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0293700.ref064" ref-type="bibr">64</xref>, <xref rid="pone.0293700.ref089" ref-type="bibr">89</xref>], <italic toggle="yes">TFRC</italic> correlated with a set of genes associated with highest proliferation in breast cancer [<xref rid="pone.0293700.ref062" ref-type="bibr">62</xref>] (<xref rid="pone.0293700.s002" ref-type="supplementary-material">S1C Fig</xref>). Negative correlation with ER [<xref rid="pone.0293700.ref061" ref-type="bibr">61</xref>, <xref rid="pone.0293700.ref063" ref-type="bibr">63</xref>] and PR and lower expression in luminal subtypes were also confirmed for <italic toggle="yes">TFRC</italic> RNA. Immunohistochemistry (IHC) was also consistent with previous reports, showing an average of 70% (range 45&#x02013;95%) TfR-high staining across all tumor stages and subtypes. In fact, ER+ and slower growing luminal A tumors could express TfR at high levels; vice-versa, TNBC or high-grade tumors could show weak TfR staining.</p><p>Previous studies reported that transferrin overexpression in the primary tumor at diagnosis predicted decreased response to drugs [<xref rid="pone.0293700.ref062" ref-type="bibr">62</xref>], and actively promote the development of metastases [<xref rid="pone.0293700.ref066" ref-type="bibr">66</xref>]. Here, we investigated the expression of TfR in the tissue of breast cancer <italic toggle="yes">after</italic> neoadjuvant therapy and once metastases had already occurred.</p><p>Gene expression and IHC of breast cancer tissue showed no significant differences in TfR expression in patients treated with most chemotherapeutics. An exception were regimens based on trastuzumab [<xref rid="pone.0293700.ref039" ref-type="bibr">39</xref>, <xref rid="pone.0293700.ref045" ref-type="bibr">45</xref>, <xref rid="pone.0293700.ref070" ref-type="bibr">70</xref>], which inhibits signaling upstream of overexpression [<xref rid="pone.0293700.ref017" ref-type="bibr">17</xref>] and decreased <italic toggle="yes">TFRC</italic> expression in all post-NAC tumors (Figs <xref rid="pone.0293700.g002" ref-type="fig">2A</xref> and <xref rid="pone.0293700.s003" ref-type="supplementary-material">S2I</xref>). No association was found between TfR expression and previous treatments with other regimens (Figs <xref rid="pone.0293700.g002" ref-type="fig">2</xref> and <xref rid="pone.0293700.s003" ref-type="supplementary-material">S2</xref> and <xref rid="pone.0293700.s004" ref-type="supplementary-material">S3</xref>).</p><p>Despite being the major determinant of mortality in breast cancer, metastases are generally underrepresented in studies of patient samples. In a custom-made TMA with matched samples from primary tumor vs bone metastases IHC showed that most patients with TfR-positive primary tumors retained expression of TfR in bone metastases, and 63% of tumors that were negative would express TfR in the metastatic site (<xref rid="pone.0293700.g003" ref-type="fig">Fig 3</xref>).</p><p>Similar to patients, preclinical models showed generally high but variable TfR expression in primary and metastatic sites. Uptake of fluorescently-labeled transferrin was evaluated in mice with disseminated 4T1 or Bo1 tumors (Figs <xref rid="pone.0293700.g004" ref-type="fig">4</xref>&#x02013;<xref rid="pone.0293700.g007" ref-type="fig">7</xref>). By ex vivo imaging, uptake of Tf was significantly higher in the spine of tumor bearing mice than controls. In other sites of metastases, uptake could be very variable or no higher than non-tumor.</p><p>Of note, in metastatic models, tumor foci are often multiple, usually smaller, and intrinsically more variable within or across individuals (<xref rid="pone.0293700.s005" ref-type="supplementary-material">S4G-S4I Fig</xref>). More to the point, while in primary tumors cancer cells constitute 50% or more of a well-defined region, metastases are surrounded by the non-tumor cells of the native tissue. For molecular imaging, such as 45-Ti transferrin PET [<xref rid="pone.0293700.ref010" ref-type="bibr">10</xref>], this challenges both elements of the signal to noise ratio (SNR). Fewer cancer cells grouped in a sub-millimetric metastasis collectively take up less tracer (low S) than a large tumor (high S). As the &#x0201c;noise&#x0201d; depends on uptake from the surrounding tissue, organs with physiologically high uptake of transferrin (e.g. the liver) will have higher noise than tissues with different functions (e.g. non-tumor fat pads) (Figs <xref rid="pone.0293700.g004" ref-type="fig">4</xref> and <xref rid="pone.0293700.s005" ref-type="supplementary-material">S4E</xref> and <xref rid="pone.0293700.s007" ref-type="supplementary-material">S6A and S6B</xref>). Overall, metastatic models are therefore a stricter challenge than the initial tests on primary tumors. In this study, the performance of tumor Tf- imaging in this more stringent test motivated the search for a way to improve the uptake of transferrin conjugates by cancer cells.</p><p>Breast cancer cells upregulate TfR through both oncogenic [<xref rid="pone.0293700.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0293700.ref017" ref-type="bibr">17</xref>] and iron regulatory signaling networks [<xref rid="pone.0293700.ref015" ref-type="bibr">15</xref>, <xref rid="pone.0293700.ref017" ref-type="bibr">17</xref>, <xref rid="pone.0293700.ref018" ref-type="bibr">18</xref>]. In vitro, loss of TfR function, Tf starvation, or long-term potent iron chelation inhibit growth and viability of breast cancer cells [<xref rid="pone.0293700.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0293700.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0293700.ref030" ref-type="bibr">30</xref>, <xref rid="pone.0293700.ref082" ref-type="bibr">82</xref>, <xref rid="pone.0293700.ref083" ref-type="bibr">83</xref>, <xref rid="pone.0293700.ref090" ref-type="bibr">90</xref>]. The adaptive response to iron scarcity is the overexpression of TfR, observed in breast cancer experiments [<xref rid="pone.0293700.ref076" ref-type="bibr">76</xref>, <xref rid="pone.0293700.ref077" ref-type="bibr">77</xref>], and previously used to increase the uptake of transferrin conjugates in vitro in glioma or leukemia cells [<xref rid="pone.0293700.ref022" ref-type="bibr">22</xref>, <xref rid="pone.0293700.ref085" ref-type="bibr">85</xref>, <xref rid="pone.0293700.ref091" ref-type="bibr">91</xref>]. Here, a non-lethal treatment with DFO significantly increased binding and endocytosis of fluorescently-labeled transferrin by luminal A, luminal B, or TNBC cells in vitro (<xref rid="pone.0293700.g005" ref-type="fig">Fig 5A&#x02013;5C</xref>).</p><p>In vivo, studies of primary breast cancer showed that long-term treatment with DFO inhibitors reduced tumor growth [<xref rid="pone.0293700.ref029" ref-type="bibr">29</xref>, <xref rid="pone.0293700.ref031" ref-type="bibr">31</xref>, <xref rid="pone.0293700.ref081" ref-type="bibr">81</xref>, <xref rid="pone.0293700.ref091" ref-type="bibr">91</xref>]. In the Bo1 model of breast cancer metastases, short-term treatment with DFO did not affect tumor growth, even when administered early after engraftment (<xref rid="pone.0293700.g007" ref-type="fig">Fig 7</xref>). This could be due to the prevalence of the microenvironment [<xref rid="pone.0293700.ref092" ref-type="bibr">92</xref>], where myeloid cells can secrete transferrin supporting metastatic growth [<xref rid="pone.0293700.ref093" ref-type="bibr">93</xref>], or to overall lower dosing. In both patients [<xref rid="pone.0293700.ref094" ref-type="bibr">94</xref>] and mice [<xref rid="pone.0293700.ref078" ref-type="bibr">78</xref>, <xref rid="pone.0293700.ref079" ref-type="bibr">79</xref>] long-term high-dose DFO can strain systemic iron metabolism, reflected in reduced ferritin levels. In our short treatment regimen, however, mouse ferritin levels remained normal (<xref rid="pone.0293700.g005" ref-type="fig">Fig 5F</xref>). This suggests that short-term DFO treatment may be able to elicit adaptive upregulation of TfR without inducing cytoreductive nor potentially toxic iron starvation. In the Bo1 metastatic model, <italic toggle="yes">in vivo</italic> and <italic toggle="yes">ex vivo</italic> imaging showed that short-term DFO treatment improved uptake of fluorescently-labeled transferrin at tumor sites. DFO-treated mice showed stronger correlation between tumor burden and AF570-Tf relative to vehicle treated controls (Figs <xref rid="pone.0293700.g006" ref-type="fig">6</xref> and <xref rid="pone.0293700.g007" ref-type="fig">7</xref>, <xref rid="pone.0293700.s007" ref-type="supplementary-material">S6</xref> and <xref rid="pone.0293700.s008" ref-type="supplementary-material">S7</xref>). Further, more metastatic foci accumulated labeled transferrin in DFO- versus vehicle-treated mice (Figs <xref rid="pone.0293700.g006" ref-type="fig">6</xref> and <xref rid="pone.0293700.g007" ref-type="fig">7</xref>). These findings suggest that treatment with DFO could improve localization of TfR-targeted biomaterials to metastatic breast cancer without disrupting systemic iron homeostasis.</p><p>Preclinical studies in breast cancer showed potential effects of iron chelators in reducing tumor growth [<xref rid="pone.0293700.ref030" ref-type="bibr">30</xref>, <xref rid="pone.0293700.ref031" ref-type="bibr">31</xref>, <xref rid="pone.0293700.ref033" ref-type="bibr">33</xref>, <xref rid="pone.0293700.ref077" ref-type="bibr">77</xref>, <xref rid="pone.0293700.ref081" ref-type="bibr">81</xref>] or enhancing chemotherapy [<xref rid="pone.0293700.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0293700.ref031" ref-type="bibr">31</xref>, <xref rid="pone.0293700.ref090" ref-type="bibr">90</xref>]. Clinical studies are currently ongoing in breast cancer (e.g.NCT05300958, NCT04435028) and other tumors (NCT05184816, NCT03652467). However, encouraging safety data derives from chelation in other non-iron overload conditions [<xref rid="pone.0293700.ref095" ref-type="bibr">95</xref>&#x02013;<xref rid="pone.0293700.ref099" ref-type="bibr">99</xref>], and other solid tumors [<xref rid="pone.0293700.ref100" ref-type="bibr">100</xref>, <xref rid="pone.0293700.ref101" ref-type="bibr">101</xref>]. In thsese, reactions to DFO were mostly low-grade toxicity, such as irritation at site of injection and anorexia in up to 25% of patients [<xref rid="pone.0293700.ref097" ref-type="bibr">97</xref>, <xref rid="pone.0293700.ref098" ref-type="bibr">98</xref>, <xref rid="pone.0293700.ref101" ref-type="bibr">101</xref>, <xref rid="pone.0293700.ref102" ref-type="bibr">102</xref>]. Grade 2&#x02013;3 adverse events were rare and reversible at discontinuation of DFO treatment [<xref rid="pone.0293700.ref097" ref-type="bibr">97</xref>, <xref rid="pone.0293700.ref101" ref-type="bibr">101</xref>], and no grade 4 adverse events were reported [<xref rid="pone.0293700.ref097" ref-type="bibr">97</xref>, <xref rid="pone.0293700.ref098" ref-type="bibr">98</xref>, <xref rid="pone.0293700.ref101" ref-type="bibr">101</xref>, <xref rid="pone.0293700.ref102" ref-type="bibr">102</xref>]. Deferiprone [<xref rid="pone.0293700.ref095" ref-type="bibr">95</xref>, <xref rid="pone.0293700.ref096" ref-type="bibr">96</xref>, <xref rid="pone.0293700.ref099" ref-type="bibr">99</xref>] and deferasirox [<xref rid="pone.0293700.ref103" ref-type="bibr">103</xref>] are iron chelators that are orally available. In conditions without iron overload, they are reported to be more potent and convenient, but associated with greater side-effects, including QT-prolongation [<xref rid="pone.0293700.ref099" ref-type="bibr">99</xref>], reversible renal [<xref rid="pone.0293700.ref103" ref-type="bibr">103</xref>] or hepatic dysfunction [<xref rid="pone.0293700.ref099" ref-type="bibr">99</xref>], and neutropenia up to grade 4 agranulochytosis [<xref rid="pone.0293700.ref095" ref-type="bibr">95</xref>, <xref rid="pone.0293700.ref096" ref-type="bibr">96</xref>, <xref rid="pone.0293700.ref099" ref-type="bibr">99</xref>, <xref rid="pone.0293700.ref103" ref-type="bibr">103</xref>]. While no patients developed anemia or sideropenia, all patients treated with iron chelators showed decrease in ferritinemia over months of treatment. In our experiments, short-term DFO did not affect serum ferritin levels. While cytoreductive protocols may require more potent and higher dose chelators, this data suggests that short-term administration of DFO to enhance the uptake of transferrin conjugates may be safe and well tolerated.</p><p>Transferrin targeting for breast cancer has been developed into promising technologies [<xref rid="pone.0293700.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0293700.ref007" ref-type="bibr">7</xref>&#x02013;<xref rid="pone.0293700.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0293700.ref022" ref-type="bibr">22</xref>, <xref rid="pone.0293700.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0293700.ref025" ref-type="bibr">25</xref>, <xref rid="pone.0293700.ref026" ref-type="bibr">26</xref>, <xref rid="pone.0293700.ref028" ref-type="bibr">28</xref>, <xref rid="pone.0293700.ref083" ref-type="bibr">83</xref>, <xref rid="pone.0293700.ref085" ref-type="bibr">85</xref>&#x02013;<xref rid="pone.0293700.ref087" ref-type="bibr">87</xref>]. By showing overexpression of transferrin receptor in metastatic and pre-treated breast tumors from a large population, our study expands on the potential indications of transferrin conjugates for drug delivery or imaging. At the same time, we show that in individual tumors and cells, expression of the receptor and uptake of Tf-conjugates can be variable, and subject to changes. This suggests that TfR-directed nanotechnologies should follow a theranostic approach, whereby binding of the homing ligand is verified by imaging prior to or while administering targeted treatments. Further, combination with FDA-approved iron chelators may improve delivery of TfR-targeting agents to breast cancer metastases, potentially improving specificity of delivery and efficacy of treatments. Studies are currently underway to evaluate therapeutic uses of TfR-targeting, enhanced by iron chelation, of breast cancer and the macrophages in the tumor microenvironment, and their potential use to sensitize breast cancer to chemo- and immunotherapy.</p></sec><sec sec-type="conclusions" id="sec024"><title>5. Conclusions</title><p>A wide survey shows high expression of transferrin receptor not only in primary breast tumors, but also in refractory/relapsing breast cancer and its visceral and bone metastases. In these severe cases, molecular targeting through transferrin receptor could be a promising strategy to develop efficacious treatments to improve survival. <italic toggle="yes">Due to variability of expression</italic>, <italic toggle="yes">combinations with molecular imaging or use of theranostics may be necessary to identify patients with highest target expression</italic>. Systemic manipulation of iron availability through non-toxic chelators could increase transferrin uptake by cancer cells, boosting the efficacy of targeted therapies.</p></sec><sec id="sec025" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pone.0293700.s001" position="float" content-type="local-data"><label>S1 Table</label><caption><title>Cancer vs non-tumor tissue expression of <italic toggle="yes">TFRC</italic> from the GENT2 database; P value for T-test of cancer vs non-cancer and Log 2 of fold-change (Log2 FC).</title><p>(PDF)</p></caption><media xlink:href="pone.0293700.s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="pone.0293700.s002" position="float" content-type="local-data"><label>S1 Fig</label><caption><p>A, B) Expression of TFRC in breast cancer versus normal tissue in A) the TGCA dataset (N = 6041) and B) GENT2 dataset (N = 1211), C) Correlation matrix of expression level (TPM) of TFRC with proliferation-associated genes (MKI67, CCNB1, CCNA2, CDK2, CDK4, CDK6, TOP2A, TOP1), oncogenes (MYC, NRAS, KRAS), receptors (ESR1, ESR2, PGR, ERBB2/Her2) and iron regulatory IREB2 in breast cancer (N = 1097 tumors from TGCA), color scale/cell numbers: Pearson&#x02019;s correlation r. D-F) Tumor microarray IHC for TfR H-scoring D) representative images of scores 0, 1, 2, 3, E, F) H-score of breast cancer samples based on TNM staging (total N = 87) E) by tumor score T, F) by lymph node score N.</p><p>(PNG)</p></caption><media xlink:href="pone.0293700.s002.png"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="pone.0293700.s003" position="float" content-type="local-data"><label>S2 Fig</label><caption><p>A) TFRC expression in TCGA samples stratified by previous exposure to chemotherapy; B, C) Expression of CDKN1 (p21, affected by epirubicin and taxanes) in B) GSE21974 dataset of breast cancer biopsies f before (Pre) and after neoadjuvant chemotherapy with four cycles of epirubicin and cyclophosphamide prior to taxane (NAC;EC-T); C) in GSE18728 in the diagnostic biopsy (pre), in biopsy after one cycle (Cy Tx), and at tumor resection (Res) D, E) in dataset GSE28826 of 14 patient-matched samples of breast cancer before (pre) and after NAC with taxanes and antracyclins (NAC:AT) D) expression of CDKN1 (p21) and E) of TFRC; F, G) In GSE153470 of patients before (Pre) and after (Post-AI) endocrine therapy with aromatase inhibitors, expression of F) of CCND1 (affected by aromatase inhibitors) and G) TFRC; H) In GSE114082 expression of CCND1 in matched Her2+ breast cancer pre- and post- NAC with trastuzumab; I) In GSE130788 expression of TFRC in HER2+ breast tumors (N = 99 samples) at baseline versus after six cycles of NAC with taxane, carboplatin, and Her2 inhibitors: TCTy (docetaxel, carboplatin, Lapatinib, N = 29 patients), TCHTy (docetaxel, carboplatin, trastuzumab, lapatinib, N = 38), TCH (docetaxel, carboplatin, trastuzumab, N = 31). J) waterfall plot of H-score in matched TNBC biopsies before versus after NAC (N = 6 patients).</p><p>(PNG)</p></caption><media xlink:href="pone.0293700.s003.png"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="pone.0293700.s004" position="float" content-type="local-data"><label>S3 Fig</label><caption><p>A) WHIM69 were treated with paclitaxel (30mg/kg) and carboplatin (50mg/kg) (Carbotaxol) versus vehicle on days 44,51,42 from implant; vehicle-treated tumors were harvested on day 62, NAC on day 111, and relapse 119 days later; treatment scheme, representative images of TfR staining and quantification scatter plot post-vehicle, post-NAC, and at relapse; B) Tfrc expression in GSE165393 set of spontaneous metastases of the MMTV-PYMT breast cancer model (N = 2); C) GSE62598 expression of tfrc in 4T1 murine TNBC isolated cells, orthotopic primary tumor, or metastases to bone, liver, or lung (N = 3); D) IHC scoring for Bo1 tumors from injection in the mammary fat pad (MFP, N = 2) or growing after left-ventricle injection as metastasis to the kidney, lung, or bone; E, F) TfR IHC of 4T1 MFP tumors (N = 4), and intracardiac injection-induced metastases to the kidneys (N = 1), lungs (N = 6), or bones (N = 2) as E) representative images, F) TfR H-Score.</p><p>(PNG)</p></caption><media xlink:href="pone.0293700.s004.png"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="pone.0293700.s005" position="float" content-type="local-data"><label>S4 Fig</label><caption><p>A) Representative images of in vivo and ex-vivo epifluorescence imaging of non-tumor bearing C57Bl/6 before, 10 minutes, 6h, and 24h post injection of AF750-Tf (left) and liver, kidneys, lungs, and legs of mice 24h from injection of vehicle (PBS, left) versus AF750-Tf (right); B-D) gene expression of Tfrc (teal) and Tfr2 (plum) in three independent normal mouse transcriptome on gene expression Atlas; E) correlation between organ expression of Tfrc and Tfr2 and uptake of AF750-Tf in the same organ; x axis: sum of the average expression of Tfrc and Tfr2 in TPM; y axis: logarithm of the difference between average radiant efficiency in the organ ROI and in the background (&#x00394;AF750-Tf av) in healthy mice 24h after ATF750-Tf injection. F-I) in 4T1 tumor bearing mice (4T1 i.c. day 12) versus control mice (No Tumor) injected with AF680-Tf, F) average radiance of in vivo BLI at day 12 in ventral and dorsal positions, G-H) total radiance in ex-vivo BLI in lungs, kidneys, legs, and spine of mice sacrificed (G) 6h and (H) 24h from AF680-Tf injection, I) comparison of ex-vivo AF680-Tf and BLI images of leg bones.</p><p>(PNG)</p></caption><media xlink:href="pone.0293700.s005.png"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="pone.0293700.s006" position="float" content-type="local-data"><label>S5 Fig</label><caption><p>A) live cell optical microscopy showing uptake of AF488-Tf in MCF7 cells in normal growing conditions, exposed to FAC 100&#x003bc;M, or DFO 100&#x003bc;M; blue Hoechst, green AF488-Tf; B, C) AF488-Tf uptake by T47D cells pre- treated 24h; B) 80 &#x003bc;M DFO vs. vehicle, C) 100 &#x003bc;M DFO or &#x003bc;M FAC vs vehicle; 488/Hoechst fluorescence intensity. D) maintenance of body weight in non tumor-bearing mice treated with six injections of HBSS (vehicle, black), DFO 100mg/kg (teal), or DFO 200mg/kg (red). E) body weight at day 11 relative to day of intracardiac tumor inoculation of Bo1 mice treated with vehicle (teal), or Bo1 mice treated with DFO 200mg/kg (red), or non-tumor bearing controls (grey); black line 100% (no change), red line critical weight loss of 20% (none recorded in this study).</p><p>(PNG)</p></caption><media xlink:href="pone.0293700.s006.png"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="pone.0293700.s007" position="float" content-type="local-data"><label>S6 Fig</label><caption><p>A) AF750-Tf uptake in the liver by total radiant efficiency in non-tumor (grey), day 11 Bo1 tumor bearing vehicle-treated (teal) or Bo1 DFO-treated (red) mice in group 1 organs lungs, liver, and kidneys B) representative examples of BLI (top, radiance in rainbow pseudocolor scale) and AF750-Tf imaging (bottom, radiant efficiency in blue hot scale) of lungs from non tumor bearing (No Tumor, left), day 11 Bo1 tumor bearing mice treated with vehicle (Bo1 Vehicle, central), and day 11 Bo1 mice treated with DFO (Bo1 DFO, right); C, D) correlation between correlation between BLI (log of average radiance) and AF750-Tf (log average radiance efficiency) in rectangular ROI on soft tissues/organs with low incidence of metastases and/or high basal uptake in Bo1 mice treated with vehicle (left) or DFO (right); D) comparison of ex-vivo BLI and AF750-Tf imaging in three representative Bo1 mice per treatment (medium, non detectable, high) treated with vehicle (left) or DFO (right); E) AF750-Tf uptake in the leg bones by total radiant efficiency in day 11 Bo1 mice treated with vehicle (teal) or DFO (red) versus non-tumor controls (grey). ***P&#x0003c;0.001 by one-way ANOVA Tukey post-hoc test.</p><p>(PNG)</p></caption><media xlink:href="pone.0293700.s007.png"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="pone.0293700.s008" position="float" content-type="local-data"><label>S7 Fig</label><caption><p>A) In vivo BLI representative image (rainbow scale for radiance) at day 3 and day 5; B) maintenance of mouse weight in Bo1-injected mice treated with vehicle (N = 4, teal) or DFO (N = 6, red); C) correlation between log (average radiance) from luciferase and log (average radiance efficiency) for Tf750 in rectangular ROI on soft tissues/ visceral organs at day 6 post- Bo1 inoculation.</p><p>(PNG)</p></caption><media xlink:href="pone.0293700.s008.png"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank Julie Prior in the Optical Imaging Center and Gail Bishop for their expertise and assistance.</p></ack><glossary><title>List of abbreviations</title><def-list><def-item><term>AF750</term><def><p>Tf AlexaFluor750-conjugated transferrin</p></def></def-item><def-item><term>ANOVA</term><def><p>analysis of variance</p></def></def-item><def-item><term>BAT</term><def><p>brown adipose tissue</p></def></def-item><def-item><term>BLI</term><def><p>bioluminescence imaging</p></def></def-item><def-item><term>DFO</term><def><p>deferoxamine</p></def></def-item><def-item><term>ER</term><def><p>estrogen receptor</p></def></def-item><def-item><term>FAC</term><def><p>ferric ammonium citrate</p></def></def-item><def-item><term>FDA</term><def><p>Food and drug administration</p></def></def-item><def-item><term>FMT</term><def><p>fluorescence molecular tomography</p></def></def-item><def-item><term>FWA</term><def><p>Federal Wide Assurance</p></def></def-item><def-item><term>GENT2</term><def><p>Gene expression database of Normal and Tumor tissues</p></def></def-item><def-item><term>GEO</term><def><p>gene expression omnibus</p></def></def-item><def-item><term>GFP</term><def><p>green fluorescent protein</p></def></def-item><def-item><term>h</term><def><p>hours</p></def></def-item><def-item><term>HER2</term><def><p>human epithelial growth factor receptor 2</p></def></def-item><def-item><term>IHC</term><def><p>immunohistochemistry</p></def></def-item><def-item><term>IRP1</term><def><p>Iron responsive protein 1</p></def></def-item><def-item><term>IRP2</term><def><p>Iron responsive protein 2</p></def></def-item><def-item><term>LN</term><def><p>lymphnode</p></def></def-item><def-item><term>Luc</term><def><p>luciferase</p></def></def-item><def-item><term>MFP</term><def><p>mammary fat pad</p></def></def-item><def-item><term>NAC</term><def><p>neoadjuvant chemotherapy</p></def></def-item><def-item><term>NEAA</term><def><p>non essential amminoacids</p></def></def-item><def-item><term>OD</term><def><p>optical density</p></def></def-item><def-item><term>PDX</term><def><p>patient derived xenografts</p></def></def-item><def-item><term>PerL</term><def><p>persistent luminescence imaging</p></def></def-item><def-item><term>PR</term><def><p>progesterone receptor</p></def></def-item><def-item><term>R-LN</term><def><p>regional lymph node</p></def></def-item><def-item><term>RNAseq</term><def><p>RNA sequencing</p></def></def-item><def-item><term>ROI</term><def><p>region of interest</p></def></def-item><def-item><term>RT</term><def><p>room temperature</p></def></def-item><def-item><term>scRNAseq</term><def><p>single cell RNA sequencing</p></def></def-item><def-item><term>SD</term><def><p>standard deviation</p></def></def-item><def-item><term>SEM</term><def><p>standard error of the mea</p></def></def-item><def-item><term>TCGA</term><def><p>Cancer Genome Atlas</p></def></def-item><def-item><term>Tf</term><def><p>transferrin</p></def></def-item><def-item><term>Tf-488</term><def><p>AlexaFluor 488-conjugated human transferrin</p></def></def-item><def-item><term>TfR</term><def><p>transferrin receptor</p></def></def-item><def-item><term>TFR2</term><def><p>transferrin receptor 2</p></def></def-item><def-item><term>TMA</term><def><p>tumor microarray</p></def></def-item><def-item><term>TNBC</term><def><p>triple negative breast cancer</p></def></def-item><def-item><term>TPM</term><def><p>transcripts per million</p></def></def-item><def-item><term>WAT</term><def><p>white adipose tissue</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="pone.0293700.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Siegel</surname><given-names>RL</given-names></name>, <name><surname>Miller</surname><given-names>KD</given-names></name>, <name><surname>Jemal</surname><given-names>A</given-names></name>. <article-title>Cancer statistics, 2020</article-title>. <source>CA Cancer J Clin</source>. <year>2020</year>; <volume>70</volume>: <fpage>7</fpage>&#x02013;<lpage>30</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3322/caac.21590</pub-id>
<pub-id pub-id-type="pmid">31912902</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Van Mechelen</surname><given-names>M</given-names></name>, <name><surname>Van Herck</surname><given-names>A</given-names></name>, <name><surname>Punie</surname><given-names>K</given-names></name>, <name><surname>Nevelsteen</surname><given-names>I</given-names></name>, <name><surname>Smeets</surname><given-names>A</given-names></name>, <name><surname>Neven</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Behavior of metastatic breast cancer according to subtype</article-title>. <source>Breast Cancer Res Treat</source>. <year>2020</year>; <volume>181</volume>: <fpage>115</fpage>&#x02013;<lpage>25</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s10549-020-05597-3</pub-id>
<pub-id pub-id-type="pmid">32193802</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Allemani</surname><given-names>C</given-names></name>, <name><surname>Matsuda</surname><given-names>T</given-names></name>, <name><surname>Di Carlo</surname><given-names>V</given-names></name>, <name><surname>Harewood</surname><given-names>R</given-names></name>, <name><surname>Matz</surname><given-names>M</given-names></name>, <name><surname>Niksic</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Global surveillance of trends in cancer survival 2000&#x02013;14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries</article-title>. <source>Lancet</source>. <year>2018</year>; <volume>391</volume>: <fpage>1023</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">29395269</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Liang</surname><given-names>Y</given-names></name>, <name><surname>Zhang</surname><given-names>H</given-names></name>, <name><surname>Song</surname><given-names>X</given-names></name>, <name><surname>Yang</surname><given-names>Q</given-names></name>. <article-title>Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets</article-title>. <source>Semin Cancer Biol</source>. <year>2020</year>; <volume>60</volume>: <fpage>14</fpage>&#x02013;<lpage>27</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.semcancer.2019.08.012</pub-id>
<pub-id pub-id-type="pmid">31421262</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Tan</surname><given-names>Y</given-names></name>, <name><surname>Liu</surname><given-names>W</given-names></name>, <name><surname>Zhu</surname><given-names>Z</given-names></name>, <name><surname>Lang</surname><given-names>L</given-names></name>, <name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Huang</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Selection and identification of transferrin receptor-specific peptides as recognition probes for cancer cells</article-title>. <source>Anal Bioanal Chem</source>. <year>2018</year>; <volume>410</volume>: <fpage>1071</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00216-017-0664-4</pub-id>
<pub-id pub-id-type="pmid">29046922</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Torti</surname><given-names>SV</given-names></name>, <name><surname>Torti</surname><given-names>FM</given-names></name>. <article-title>Cellular iron metabolism in prognosis and therapy of breast cancer</article-title>. <source>Crit Rev Oncog</source>. <year>2013</year>; <volume>18</volume>: <fpage>435</fpage>&#x02013;<lpage>48</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1615/critrevoncog.2013007784</pub-id>
<pub-id pub-id-type="pmid">23879588</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>DC</given-names></name>, <name><surname>Jiang</surname><given-names>XP</given-names></name>, <name><surname>Elliott</surname><given-names>RL</given-names></name>, <name><surname>Head</surname><given-names>JF</given-names></name>. <article-title>Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene</article-title>. <source>Anticancer Res</source>. <year>2001</year>; <volume>21</volume>: <fpage>1777</fpage>&#x02013;<lpage>87</lpage>. <pub-id pub-id-type="pmid">11497259</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Henry</surname><given-names>KE</given-names></name>, <name><surname>Dilling</surname><given-names>TR</given-names></name>, <name><surname>Abdel-Atti</surname><given-names>D</given-names></name>, <name><surname>Edwards</surname><given-names>KJ</given-names></name>, <name><surname>Evans</surname><given-names>MJ</given-names></name>, <name><surname>Lewis</surname><given-names>JS</given-names></name>. <article-title>Noninvasive (89)Zr-Transferrin PET Shows Improved Tumor Targeting Compared with (18)F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer</article-title>. <source>J Nucl Med</source>. <year>2018</year>; <volume>59</volume>: <fpage>51</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2967/jnumed.117.192286</pub-id>
<pub-id pub-id-type="pmid">28848040</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Soe</surname><given-names>ZC</given-names></name>, <name><surname>Kwon</surname><given-names>JB</given-names></name>, <name><surname>Thapa</surname><given-names>RK</given-names></name>, <name><surname>Ou</surname><given-names>W</given-names></name>, <name><surname>Nguyen</surname><given-names>HT</given-names></name>, <name><surname>Gautam</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Transferrin-Conjugated Polymeric Nanoparticle for Receptor-Mediated Delivery of Doxorubicin in Doxorubicin-Resistant Breast Cancer Cells</article-title>. <source>Pharmaceutics</source>. <year>2019</year>; <volume>11</volume>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/pharmaceutics11020063</pub-id>
<pub-id pub-id-type="pmid">30717256</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Vavere</surname><given-names>AL</given-names></name>, <name><surname>Welch</surname><given-names>MJ</given-names></name>. <article-title>Preparation, biodistribution, and small animal PET of 45Ti-transferrin</article-title>. <source>J Nucl Med</source>. <year>2005</year>; <volume>46</volume>: <fpage>683</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="pmid">15809492</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Elliott</surname><given-names>RL</given-names></name>, <name><surname>Stjernholm</surname><given-names>R</given-names></name>, <name><surname>Elliott</surname><given-names>MC</given-names></name>. <article-title>Preliminary evaluation of platinum transferrin (MPTC-63) as a potential nontoxic treatment for breast cancer</article-title>. <source>Cancer Detect Prev</source>. <year>1988</year>; <volume>12</volume>: <fpage>469</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="pmid">3180141</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Wigner</surname><given-names>P</given-names></name>, <name><surname>Zielinski</surname><given-names>K</given-names></name>, <name><surname>Labieniec-Watala</surname><given-names>M</given-names></name>, <name><surname>Marczak</surname><given-names>A</given-names></name>, <name><surname>Szwed</surname><given-names>M</given-names></name>. <article-title>Doxorubicin-transferrin conjugate alters mitochondrial homeostasis and energy metabolism in human breast cancer cells</article-title>. <source>Sci Rep</source>. <year>2021</year>; <volume>11</volume>: <fpage>4544</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-021-84146-4</pub-id>
<pub-id pub-id-type="pmid">33633284</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Wei</surname><given-names>Y</given-names></name>, <name><surname>Sun</surname><given-names>Y</given-names></name>, <name><surname>Wei</surname><given-names>J</given-names></name>, <name><surname>Qiu</surname><given-names>X</given-names></name>, <name><surname>Meng</surname><given-names>F</given-names></name>, <name><surname>Storm</surname><given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Selective transferrin coating as a facile strategy to fabricate BBB-permeable and targeted vesicles for potent RNAi therapy of brain metastatic breast cancer in vivo</article-title>. <source>J Control Release</source>. <year>2021</year>; <volume>337</volume>: <fpage>521</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jconrel.2021.07.048</pub-id>
<pub-id pub-id-type="pmid">34352315</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Lane</surname><given-names>DD</given-names></name>, <name><surname>Black</surname><given-names>KCL</given-names></name>, <name><surname>Raliya</surname><given-names>R</given-names></name>, <name><surname>Reed</surname><given-names>N</given-names></name>, <name><surname>Kotagiri</surname><given-names>N</given-names></name>, <name><surname>Gilson</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Effects of core titanium crystal dimension and crystal phase on ROS generation and tumour accumulation of transferrin coated titanium dioxide nanoaggregates</article-title>. <source>RSC Adv</source>. <year>2020</year>; <volume>10</volume>: <fpage>23759</fpage>&#x02013;<lpage>66</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1039/d0ra01878c</pub-id>
<pub-id pub-id-type="pmid">32774845</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>W</given-names></name>, <name><surname>Deng</surname><given-names>Z</given-names></name>, <name><surname>Hatcher</surname><given-names>H</given-names></name>, <name><surname>Miller</surname><given-names>LD</given-names></name>, <name><surname>Di</surname><given-names>X</given-names></name>, <name><surname>Tesfay</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>IRP2 regulates breast tumor growth</article-title>. <source>Cancer Res</source>. <year>2014</year>; <volume>74</volume>: <fpage>497</fpage>&#x02013;<lpage>507</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-1224</pub-id>
<pub-id pub-id-type="pmid">24285726</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Marques</surname><given-names>O</given-names></name>, <name><surname>da Silva</surname><given-names>BM</given-names></name>, <name><surname>Porto</surname><given-names>G</given-names></name>, <name><surname>Lopes</surname><given-names>C</given-names></name>. <article-title>Iron homeostasis in breast cancer</article-title>. <source>Cancer Lett</source>. <year>2014</year>; <volume>347</volume>: <fpage>1</fpage>&#x02013;<lpage>14</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.canlet.2014.01.029</pub-id>
<pub-id pub-id-type="pmid">24486738</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Chifman</surname><given-names>J</given-names></name>, <name><surname>Arat</surname><given-names>S</given-names></name>, <name><surname>Deng</surname><given-names>Z</given-names></name>, <name><surname>Lemler</surname><given-names>E</given-names></name>, <name><surname>Pino</surname><given-names>JC</given-names></name>, <name><surname>Harris</surname><given-names>LA</given-names></name>, <etal>et al</etal>. <article-title>Activated Oncogenic Pathway Modifies Iron Network in Breast Epithelial Cells: A Dynamic Modeling Perspective</article-title>. <source>PLoS Comput Biol</source>. <year>2017</year>; <volume>13</volume>: <fpage>e1005352</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pcbi.1005352</pub-id>
<pub-id pub-id-type="pmid">28166223</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Miyazawa</surname><given-names>M</given-names></name>, <name><surname>Bogdan</surname><given-names>AR</given-names></name>, <name><surname>Tsuji</surname><given-names>Y</given-names></name>. <article-title>Perturbation of Iron Metabolism by Cisplatin through Inhibition of Iron Regulatory Protein 2</article-title>. <source>Cell Chem Biol</source>. <year>2019</year>; <volume>26</volume>: <fpage>85</fpage>&#x02013;<lpage>97</lpage> e4. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.chembiol.2018.10.009</pub-id>
<pub-id pub-id-type="pmid">30449675</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Allegra</surname><given-names>JC</given-names></name>, <name><surname>Lippman</surname><given-names>ME</given-names></name>. <article-title>Growth of a human breast cancer cell line in serum-free hormone-supplemented medium</article-title>. <source>Cancer Res</source>. <year>1978</year>; <volume>38</volume>: <fpage>3823</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="pmid">212180</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Faulk</surname><given-names>WP</given-names></name>, <name><surname>Hsi</surname><given-names>BL</given-names></name>, <name><surname>Stevens</surname><given-names>PJ</given-names></name>. <article-title>Transferrin and transferrin receptors in carcinoma of the breast</article-title>. <source>Lancet</source>. <year>1980</year>; <volume>2</volume>: <fpage>390</fpage>&#x02013;<lpage>2</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0140-6736(80)90440-7</pub-id>
<pub-id pub-id-type="pmid">6105517</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Wrba</surname><given-names>F</given-names></name>, <name><surname>Ritzinger</surname><given-names>E</given-names></name>, <name><surname>Reiner</surname><given-names>A</given-names></name>, <name><surname>Holzner</surname><given-names>JH</given-names></name>. <article-title>Transferrin receptor (TrfR) expression in breast carcinoma and its possible relationship to prognosis</article-title>. <source>An immunohistochemical study. Virchows Arch A Pathol Anat Histopathol</source>. <year>1986</year>; <volume>410</volume>: <fpage>69</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">3024390</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>X</given-names></name>, <name><surname>Koh</surname><given-names>CG</given-names></name>, <name><surname>Liu</surname><given-names>S</given-names></name>, <name><surname>Pan</surname><given-names>X</given-names></name>, <name><surname>Santhanam</surname><given-names>R</given-names></name>, <name><surname>Yu</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2</article-title>. <source>Mol Pharm</source>. <year>2009</year>; <volume>6</volume>: <fpage>221</fpage>&#x02013;<lpage>30</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/mp800149s</pub-id>
<pub-id pub-id-type="pmid">19183107</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Kotagiri</surname><given-names>N</given-names></name>, <name><surname>Sudlow</surname><given-names>GP</given-names></name>, <name><surname>Akers</surname><given-names>WJ</given-names></name>, <name><surname>Achilefu</surname><given-names>S</given-names></name>. <article-title>Breaking the depth dependency of phototherapy with Cerenkov radiation and low-radiance-responsive nanophotosensitizers</article-title>. <source>Nat Nanotechnol</source>. <year>2015</year>; <volume>10</volume>: <fpage>370</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nnano.2015.17</pub-id>
<pub-id pub-id-type="pmid">25751304</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>G</given-names></name>, <name><surname>Kumar</surname><given-names>A</given-names></name>, <name><surname>Ding</surname><given-names>W</given-names></name>, <name><surname>Korangath</surname><given-names>P</given-names></name>, <name><surname>Bera</surname><given-names>T</given-names></name>, <name><surname>Wei</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Intraductal administration of transferrin receptor-targeted immunotoxin clears ductal carcinoma in situ in mouse models of breast cancer-a preclinical study</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2022</year>; <volume>119</volume>: <fpage>e2200200119</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.2200200119</pub-id>
<pub-id pub-id-type="pmid">35675429</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Abe</surname><given-names>K</given-names></name>, <name><surname>Zhao</surname><given-names>L</given-names></name>, <name><surname>Periasamy</surname><given-names>A</given-names></name>, <name><surname>Intes</surname><given-names>X</given-names></name>, <name><surname>Barroso</surname><given-names>M</given-names></name>. <article-title>Non-invasive in vivo imaging of near infrared-labeled transferrin in breast cancer cells and tumors using fluorescence lifetime FRET</article-title>. <source>PLoS One</source>. <year>2013</year>; <volume>8</volume>: <fpage>e80269</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0080269</pub-id>
<pub-id pub-id-type="pmid">24278268</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Tseng</surname><given-names>JC</given-names></name>, <name><surname>Narayanan</surname><given-names>N</given-names></name>, <name><surname>Ho</surname><given-names>G</given-names></name>, <name><surname>Groves</surname><given-names>K</given-names></name>, <name><surname>Delaney</surname><given-names>J</given-names></name>, <name><surname>Bao</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Fluorescence imaging of bombesin and transferrin receptor expression is comparable to 18F-FDG PET in early detection of sorafenib-induced changes in tumor metabolism</article-title>. <source>PLoS One</source>. <year>2017</year>; <volume>12</volume>: <fpage>e0182689</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0182689</pub-id>
<pub-id pub-id-type="pmid">28792505</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Xie</surname><given-names>BW</given-names></name>, <name><surname>Mol</surname><given-names>IM</given-names></name>, <name><surname>Keereweer</surname><given-names>S</given-names></name>, <name><surname>van Beek</surname><given-names>ER</given-names></name>, <name><surname>Que</surname><given-names>I</given-names></name>, <name><surname>Snoeks</surname><given-names>TJ</given-names></name>, <etal>et al</etal>. <article-title>Dual-wavelength imaging of tumor progression by activatable and targeting near-infrared fluorescent probes in a bioluminescent breast cancer model</article-title>. <source>PLoS One</source>. <year>2012</year>; <volume>7</volume>: <fpage>e31875</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0031875</pub-id>
<pub-id pub-id-type="pmid">22348134</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>J</given-names></name>, <name><surname>Yang</surname><given-names>Q</given-names></name>, <name><surname>Xu</surname><given-names>L</given-names></name>, <name><surname>Lou</surname><given-names>J</given-names></name>, <name><surname>Dong</surname><given-names>Z</given-names></name>. <article-title>An epirubicin-peptide conjugate with anticancer activity is dependent upon the expression level of the surface transferrin receptor</article-title>. <source>Mol Med Rep</source>. <year>2017</year>; <volume>15</volume>: <fpage>323</fpage>&#x02013;<lpage>30</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3892/mmr.2016.6004</pub-id>
<pub-id pub-id-type="pmid">27959443</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>B</given-names></name>, <name><surname>Esposito</surname><given-names>BP</given-names></name>, <name><surname>Wang</surname><given-names>S</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Xu</surname><given-names>M</given-names></name>, <name><surname>Zhang</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Desferrioxamine-caffeine shows improved efficacy in chelating iron and depleting cancer stem cells</article-title>. <source>J Trace Elem Med Biol</source>. <year>2019</year>; <volume>52</volume>: <fpage>232</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jtemb.2019.01.004</pub-id>
<pub-id pub-id-type="pmid">30732888</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Kuban-Jankowska</surname><given-names>A</given-names></name>, <name><surname>Sahu</surname><given-names>KK</given-names></name>, <name><surname>Gorska-Ponikowska</surname><given-names>M</given-names></name>, <name><surname>Tuszynski</surname><given-names>JA</given-names></name>, <name><surname>Wozniak</surname><given-names>M</given-names></name>. <article-title>Inhibitory Activity of Iron Chelators ATA and DFO on MCF-7 Breast Cancer Cells and Phosphatases PTP1B and SHP2</article-title>. <source>Anticancer Res</source>. <year>2017</year>; <volume>37</volume>: <fpage>4799</fpage>&#x02013;<lpage>806</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.21873/anticanres.11886</pub-id>
<pub-id pub-id-type="pmid">28870898</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Goto</surname><given-names>W</given-names></name>, <name><surname>Kashiwagi</surname><given-names>S</given-names></name>, <name><surname>Asano</surname><given-names>Y</given-names></name>, <name><surname>Takada</surname><given-names>K</given-names></name>, <name><surname>Morisaki</surname><given-names>T</given-names></name>, <name><surname>Takahashi</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment</article-title>. <source>BMC Cancer</source>. <year>2020</year>; <volume>20</volume>: <fpage>1215</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12885-020-07673-9</pub-id>
<pub-id pub-id-type="pmid">33302911</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Dassoulas</surname><given-names>KR</given-names></name>, <name><surname>Mericli</surname><given-names>AF</given-names></name>, <name><surname>Wang</surname><given-names>JS</given-names></name>, <name><surname>Lei</surname><given-names>SS</given-names></name>, <name><surname>Kim</surname><given-names>T</given-names></name>, <name><surname>Cottler</surname><given-names>PS</given-names></name>, <etal>et al</etal>. <article-title>Treatment With Topical Deferoxamine Improves Cutaneous Vascularity and Tissue Pliability in an Irradiated Animal Model of Tissue Expander-Based Breast Reconstruction</article-title>. <source>Ann Plast Surg</source>. <year>2019</year>; <volume>82</volume>: <fpage>104</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/SAP.0000000000001655</pub-id>
<pub-id pub-id-type="pmid">30531453</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Bajbouj</surname><given-names>K</given-names></name>, <name><surname>Shafarin</surname><given-names>J</given-names></name>, <name><surname>Hamad</surname><given-names>M</given-names></name>. <article-title>High-Dose Deferoxamine Treatment Disrupts Intracellular Iron Homeostasis, Reduces Growth, and Induces Apoptosis in Metastatic and Nonmetastatic Breast Cancer Cell Lines</article-title>. <source>Technol Cancer Res Treat</source>. <year>2018</year>; <volume>17</volume>: 1533033818764470. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/1533033818764470</pub-id>
<pub-id pub-id-type="pmid">29562821</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>SJ</given-names></name>, <name><surname>Yoon</surname><given-names>BH</given-names></name>, <name><surname>Kim</surname><given-names>SK</given-names></name>, <name><surname>Kim</surname><given-names>SY</given-names></name>. <article-title>GENT2: an updated gene expression database for normal and tumor tissues</article-title>. <source>BMC Med Genomics</source>. <year>2019</year>; <volume>12</volume>: <fpage>101</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12920-019-0514-7</pub-id>
<pub-id pub-id-type="pmid">31296229</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Creighton</surname><given-names>CJ</given-names></name>. <article-title>Making Use of Cancer Genomic Databases</article-title>. <source>Curr Protoc Mol Biol</source>. <year>2018</year>; <volume>121</volume>: <fpage>19</fpage> 4 1&#x02013;4 3. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/cpmb.49</pub-id>
<pub-id pub-id-type="pmid">29337373</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Goldman</surname><given-names>MJ</given-names></name>, <name><surname>Craft</surname><given-names>B</given-names></name>, <name><surname>Hastie</surname><given-names>M</given-names></name>, <name><surname>Repecka</surname><given-names>K</given-names></name>, <name><surname>McDade</surname><given-names>F</given-names></name>, <name><surname>Kamath</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Visualizing and interpreting cancer genomics data via the Xena platform</article-title>. <source>Nat Biotechnol</source>. <year>2020</year>; <volume>38</volume>: <fpage>675</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41587-020-0546-8</pub-id>
<pub-id pub-id-type="pmid">32444850</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Lim</surname><given-names>N</given-names></name>, <name><surname>Tesar</surname><given-names>S</given-names></name>, <name><surname>Belmadani</surname><given-names>M</given-names></name>, <name><surname>Poirier-Morency</surname><given-names>G</given-names></name>, <name><surname>Mancarci</surname><given-names>BO</given-names></name>, <name><surname>Sicherman</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Curation of over 10 000 transcriptomic studies to enable data reuse</article-title>. <source>Database (Oxford)</source>. <year>2021</year>; 2021.</mixed-citation></ref><ref id="pone.0293700.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Dunbier</surname><given-names>AK</given-names></name>, <name><surname>Ghazoui</surname><given-names>Z</given-names></name>, <name><surname>Anderson</surname><given-names>H</given-names></name>, <name><surname>Salter</surname><given-names>J</given-names></name>, <name><surname>Nerurkar</surname><given-names>A</given-names></name>, <name><surname>Osin</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance</article-title>. <source>Clin Cancer Res</source>. <year>2013</year>; <volume>19</volume>: <fpage>2775</fpage>&#x02013;<lpage>86</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-1000</pub-id>
<pub-id pub-id-type="pmid">23493347</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Triulzi</surname><given-names>T</given-names></name>, <name><surname>Regondi</surname><given-names>V</given-names></name>, <name><surname>De Cecco</surname><given-names>L</given-names></name>, <name><surname>Cappelletti</surname><given-names>MR</given-names></name>, <name><surname>Di Modica</surname><given-names>M</given-names></name>, <name><surname>Paolini</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit</article-title>. <source>Br J Cancer</source>. <year>2018</year>; <volume>119</volume>: <fpage>1487</fpage>&#x02013;<lpage>94</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41416-018-0318-0</pub-id>
<pub-id pub-id-type="pmid">30478407</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Stickeler</surname><given-names>E</given-names></name>, <name><surname>Pils</surname><given-names>D</given-names></name>, <name><surname>Klar</surname><given-names>M</given-names></name>, <name><surname>Orlowsk-Volk</surname><given-names>M</given-names></name>, <name><surname>Zur Hausen</surname><given-names>A</given-names></name>, <name><surname>Jager</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Basal-like molecular subtype and HER4 up-regulation and response to neoadjuvant chemotherapy in breast cancer</article-title>. <source>Oncol Rep</source>. <year>2011</year>; <volume>26</volume>: <fpage>1037</fpage>&#x02013;<lpage>45</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3892/or.2011.1392</pub-id>
<pub-id pub-id-type="pmid">21769435</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Korde</surname><given-names>LA</given-names></name>, <name><surname>Lusa</surname><given-names>L</given-names></name>, <name><surname>McShane</surname><given-names>L</given-names></name>, <name><surname>Lebowitz</surname><given-names>PF</given-names></name>, <name><surname>Lukes</surname><given-names>L</given-names></name>, <name><surname>Camphausen</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer</article-title>. <source>Breast Cancer Res Treat</source>. <year>2010</year>; <volume>119</volume>: <fpage>685</fpage>&#x02013;<lpage>99</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s10549-009-0651-3</pub-id>
<pub-id pub-id-type="pmid">20012355</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Hultsch</surname><given-names>S</given-names></name>, <name><surname>Kankainen</surname><given-names>M</given-names></name>, <name><surname>Paavolainen</surname><given-names>L</given-names></name>, <name><surname>Kovanen</surname><given-names>RM</given-names></name>, <name><surname>Ikonen</surname><given-names>E</given-names></name>, <name><surname>Kangaspeska</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Association of tamoxifen resistance and lipid reprogramming in breast cancer</article-title>. <source>BMC Cancer</source>. <year>2018</year>; <volume>18</volume>: <fpage>850</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12885-018-4757-z</pub-id>
<pub-id pub-id-type="pmid">30143015</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>McBryan</surname><given-names>J</given-names></name>, <name><surname>Fagan</surname><given-names>A</given-names></name>, <name><surname>McCartan</surname><given-names>D</given-names></name>, <name><surname>Bane</surname><given-names>FT</given-names></name>, <name><surname>Vareslija</surname><given-names>D</given-names></name>, <name><surname>Cocchiglia</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy</article-title>. <source>Clin Cancer Res</source>. <year>2015</year>; <volume>21</volume>: <fpage>5371</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-2155</pub-id>
<pub-id pub-id-type="pmid">26240272</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Tabaries</surname><given-names>S</given-names></name>, <name><surname>Ouellet</surname><given-names>V</given-names></name>, <name><surname>Hsu</surname><given-names>BE</given-names></name>, <name><surname>Annis</surname><given-names>MG</given-names></name>, <name><surname>Rose</surname><given-names>AA</given-names></name>, <name><surname>Meunier</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases</article-title>. <source>Breast Cancer Res</source>. <year>2015</year>; <volume>17</volume>: <fpage>45</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s13058-015-0558-3</pub-id>
<pub-id pub-id-type="pmid">25882816</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Zoeller</surname><given-names>JJ</given-names></name>, <name><surname>Press</surname><given-names>MF</given-names></name>, <name><surname>Selfors</surname><given-names>LM</given-names></name>, <name><surname>Dering</surname><given-names>J</given-names></name>, <name><surname>Slamon</surname><given-names>DJ</given-names></name>, <name><surname>Hurvitz</surname><given-names>SA</given-names></name>, <etal>et al</etal>. <article-title>Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy</article-title>. <source>PLoS One</source>. <year>2021</year>; <volume>16</volume>: <fpage>e0251163</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0251163</pub-id>
<pub-id pub-id-type="pmid">33951110</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Ionkina</surname><given-names>AA</given-names></name>, <name><surname>Balderrama-Gutierrez</surname><given-names>G</given-names></name>, <name><surname>Ibanez</surname><given-names>KJ</given-names></name>, <name><surname>Phan</surname><given-names>SHD</given-names></name>, <name><surname>Cortez</surname><given-names>AN</given-names></name>, <name><surname>Mortazavi</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Transcriptome analysis of heterogeneity in mouse model of metastatic breast cancer</article-title>. <source>Breast Cancer Res</source>. <year>2021</year>; <volume>23</volume>: <fpage>93</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s13058-021-01468-x</pub-id>
<pub-id pub-id-type="pmid">34579762</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Braso-Maristany</surname><given-names>F</given-names></name>, <name><surname>Pare</surname><given-names>L</given-names></name>, <name><surname>Chic</surname><given-names>N</given-names></name>, <name><surname>Martinez-Saez</surname><given-names>O</given-names></name>, <name><surname>Pascual</surname><given-names>T</given-names></name>, <name><surname>Mallafre-Larrosa</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Gene expression profiles of breast cancer metastasis according to organ site</article-title>. <source>Mol Oncol</source>. <year>2021</year>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/1878-0261.13021</pub-id>
<pub-id pub-id-type="pmid">34051058</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>McMullin</surname><given-names>RP</given-names></name>, <name><surname>Wittner</surname><given-names>BS</given-names></name>, <name><surname>Yang</surname><given-names>C</given-names></name>, <name><surname>Denton-Schneider</surname><given-names>BR</given-names></name>, <name><surname>Hicks</surname><given-names>D</given-names></name>, <name><surname>Singavarapu</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity</article-title>. <source>Breast Cancer Res</source>. <year>2014</year>; <volume>16</volume>: <fpage>R25</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/bcr3625</pub-id>
<pub-id pub-id-type="pmid">24625110</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Edgar</surname><given-names>R</given-names></name>, <name><surname>Domrachev</surname><given-names>M</given-names></name>, <name><surname>Lash</surname><given-names>AE</given-names></name>. <article-title>Gene Expression Omnibus: NCBI gene expression and hybridization array data repository</article-title>. <source>Nucleic Acids Res</source>. <year>2002</year>; <volume>30</volume>: <fpage>207</fpage>&#x02013;<lpage>10</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/30.1.207</pub-id>
<pub-id pub-id-type="pmid">11752295</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Chung</surname><given-names>W</given-names></name>, <name><surname>Eum</surname><given-names>HH</given-names></name>, <name><surname>Lee</surname><given-names>HO</given-names></name>, <name><surname>Lee</surname><given-names>KM</given-names></name>, <name><surname>Lee</surname><given-names>HB</given-names></name>, <name><surname>Kim</surname><given-names>KT</given-names></name>, <etal>et al</etal>. <article-title>Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer</article-title>. <source>Nat Commun</source>. <year>2017</year>; <volume>8</volume>: <fpage>15081</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/ncomms15081</pub-id>
<pub-id pub-id-type="pmid">28474673</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Papatheodorou</surname><given-names>I</given-names></name>, <name><surname>Moreno</surname><given-names>P</given-names></name>, <name><surname>Manning</surname><given-names>J</given-names></name>, <name><surname>Fuentes</surname><given-names>AM</given-names></name>, <name><surname>George</surname><given-names>N</given-names></name>, <name><surname>Fexova</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Expression Atlas update: from tissues to single cells</article-title>. <source>Nucleic Acids Res</source>. <year>2020</year>; <volume>48</volume>: <fpage>D77</fpage>&#x02013;<lpage>D83</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkz947</pub-id>
<pub-id pub-id-type="pmid">31665515</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Okazaki</surname><given-names>Y</given-names></name>, <name><surname>Furuno</surname><given-names>M</given-names></name>, <name><surname>Kasukawa</surname><given-names>T</given-names></name>, <name><surname>Adachi</surname><given-names>J</given-names></name>, <name><surname>Bono</surname><given-names>H</given-names></name>, <name><surname>Kondo</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs</article-title>. <source>Nature</source>. <year>2002</year>; <volume>420</volume>: <fpage>563</fpage>&#x02013;<lpage>73</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nature01266</pub-id>
<pub-id pub-id-type="pmid">12466851</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Ross</surname><given-names>MH</given-names></name>, <name><surname>Esser</surname><given-names>AK</given-names></name>, <name><surname>Fox</surname><given-names>GC</given-names></name>, <name><surname>Schmieder</surname><given-names>AH</given-names></name>, <name><surname>Yang</surname><given-names>X</given-names></name>, <name><surname>Hu</surname><given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Bone-Induced Expression of Integrin beta3 Enables Targeted Nanotherapy of Breast Cancer Metastases</article-title>. <source>Cancer Res</source>. <year>2017</year>; <volume>77</volume>: <fpage>6299</fpage>&#x02013;<lpage>312</lpage>.<pub-id pub-id-type="pmid">28855208</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Nunez-Torron</surname><given-names>C</given-names></name>, <name><surname>Ferrer-Gomez</surname><given-names>A</given-names></name>, <name><surname>Moreno Moreno</surname><given-names>E</given-names></name>, <name><surname>Perez-Mies</surname><given-names>B</given-names></name>, <name><surname>Villarrubia</surname><given-names>J</given-names></name>, <name><surname>Chamorro</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Secondary haemophagocytic lymphohistiocytosis in COVID-19: correlation of the autopsy findings of bone marrow haemophagocytosis with HScore</article-title>. <source>J Clin Pathol</source>. <year>2021</year>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/jclinpath-2020-207337</pub-id>
<pub-id pub-id-type="pmid">33722841</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Choudhury</surname><given-names>KR</given-names></name>, <name><surname>Yagle</surname><given-names>KJ</given-names></name>, <name><surname>Swanson</surname><given-names>PE</given-names></name>, <name><surname>Krohn</surname><given-names>KA</given-names></name>, <name><surname>Rajendran</surname><given-names>JG</given-names></name>. <article-title>A robust automated measure of average antibody staining in immunohistochemistry images</article-title>. <source>J Histochem Cytochem</source>. <year>2010</year>; <volume>58</volume>: <fpage>95</fpage>&#x02013;<lpage>107</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1369/jhc.2009.953554</pub-id>
<pub-id pub-id-type="pmid">19687472</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Xiang</surname><given-names>J</given-names></name>, <name><surname>Hurchla</surname><given-names>MA</given-names></name>, <name><surname>Fontana</surname><given-names>F</given-names></name>, <name><surname>Su</surname><given-names>X</given-names></name>, <name><surname>Amend</surname><given-names>SR</given-names></name>, <name><surname>Esser</surname><given-names>AK</given-names></name>, <etal>et al</etal>. <article-title>CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer</article-title>. <source>Mol Cancer Ther</source>. <year>2015</year>; <volume>14</volume>: <fpage>2473</fpage>&#x02013;<lpage>85</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-15-0252</pub-id>
<pub-id pub-id-type="pmid">26269605</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Ding</surname><given-names>L</given-names></name>, <name><surname>Ellis</surname><given-names>MJ</given-names></name>, <name><surname>Li</surname><given-names>S</given-names></name>, <name><surname>Larson</surname><given-names>DE</given-names></name>, <name><surname>Chen</surname><given-names>K</given-names></name>, <name><surname>Wallis</surname><given-names>JW</given-names></name>, <etal>et al</etal>. <article-title>Genome remodelling in a basal-like breast cancer metastasis and xenograft</article-title>. <source>Nature</source>. <year>2010</year>; <volume>464</volume>: <fpage>999</fpage>&#x02013;<lpage>1005</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nature08989</pub-id>
<pub-id pub-id-type="pmid">20393555</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Su</surname><given-names>X</given-names></name>, <name><surname>Esser</surname><given-names>AK</given-names></name>, <name><surname>Amend</surname><given-names>SR</given-names></name>, <name><surname>Xiang</surname><given-names>J</given-names></name>, <name><surname>Xu</surname><given-names>Y</given-names></name>, <name><surname>Ross</surname><given-names>MH</given-names></name>, <etal>et al</etal>. <article-title>Antagonizing Integrin beta3 Increases Immunosuppression in Cancer</article-title>. <source>Cancer Res</source>. <year>2016</year>; <volume>76</volume>: <fpage>3484</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">27216180</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>MC</given-names></name>, <name><surname>Luker</surname><given-names>KE</given-names></name>, <name><surname>Garbow</surname><given-names>JR</given-names></name>, <name><surname>Prior</surname><given-names>JL</given-names></name>, <name><surname>Jackson</surname><given-names>E</given-names></name>, <name><surname>Piwnica-Worms</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>CXCR4 regulates growth of both primary and metastatic breast cancer</article-title>. <source>Cancer Res</source>. <year>2004</year>; <volume>64</volume>: <fpage>8604</fpage>&#x02013;<lpage>12</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1844</pub-id>
<pub-id pub-id-type="pmid">15574767</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Faul</surname><given-names>F</given-names></name>, <name><surname>Erdfelder</surname><given-names>E</given-names></name>, <name><surname>Lang</surname><given-names>AG</given-names></name>, <name><surname>Buchner</surname><given-names>A</given-names></name>. <article-title>G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences</article-title>. <source>Behav Res Methods</source>. <year>2007</year>; <volume>39</volume>: <fpage>175</fpage>&#x02013;<lpage>91</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3758/bf03193146</pub-id>
<pub-id pub-id-type="pmid">17695343</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Henriet</surname><given-names>E</given-names></name>, <name><surname>Knutsdottir</surname><given-names>H</given-names></name>, <name><surname>Grasset</surname><given-names>EM</given-names></name>, <name><surname>Dunworth</surname><given-names>M</given-names></name>, <name><surname>Haynes</surname><given-names>M</given-names></name>, <name><surname>Bader</surname><given-names>JS</given-names></name>, <etal>et al</etal>. <article-title>Triple negative breast tumors contain heterogeneous cancer cells expressing distinct KRAS-dependent collective and disseminative invasion programs</article-title>. <source>Oncogene</source>. <year>2023</year>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41388-022-02586-2</pub-id>
<pub-id pub-id-type="pmid">36604566</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Habashy</surname><given-names>HO</given-names></name>, <name><surname>Powe</surname><given-names>DG</given-names></name>, <name><surname>Staka</surname><given-names>CM</given-names></name>, <name><surname>Rakha</surname><given-names>EA</given-names></name>, <name><surname>Ball</surname><given-names>G</given-names></name>, <name><surname>Green</surname><given-names>AR</given-names></name>, <etal>et al</etal>. <article-title>Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen</article-title>. <source>Breast Cancer Res Treat</source>. <year>2010</year>; <volume>119</volume>: <fpage>283</fpage>&#x02013;<lpage>93</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s10549-009-0345-x</pub-id>
<pub-id pub-id-type="pmid">19238537</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Tonik</surname><given-names>SE</given-names></name>, <name><surname>Shindelman</surname><given-names>JE</given-names></name>, <name><surname>Sussman</surname><given-names>HH</given-names></name>. <article-title>Transferrin receptor is inversely correlated with estrogen receptor in breast cancer</article-title>. <source>Breast Cancer Res Treat</source>. <year>1986</year>; <volume>7</volume>: <fpage>71</fpage>&#x02013;<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/BF01806791</pub-id>
<pub-id pub-id-type="pmid">3013349</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Wrba</surname><given-names>F</given-names></name>, <name><surname>Chott</surname><given-names>A</given-names></name>, <name><surname>Reiner</surname><given-names>A</given-names></name>, <name><surname>Reiner</surname><given-names>G</given-names></name>, <name><surname>Markis-Ritzinger</surname><given-names>E</given-names></name>, <name><surname>Holzner</surname><given-names>JH</given-names></name>. <article-title>Ki-67 immunoreactivity in breast carcinomas in relation to transferrin receptor expression, estrogen receptor status and morphological criteria. An immunohistochemical study</article-title>. <source>Oncology</source>. <year>1989</year>; <volume>46</volume>: <fpage>255</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1159/000226727</pub-id>
<pub-id pub-id-type="pmid">2662089</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref065"><label>65</label><mixed-citation publication-type="journal"><name><surname>Betta</surname><given-names>PG</given-names></name>, <name><surname>Robutti</surname><given-names>F</given-names></name>, <name><surname>Pilato</surname><given-names>FP</given-names></name>, <name><surname>Spinoglio</surname><given-names>G</given-names></name>, <name><surname>Bottero</surname><given-names>G</given-names></name>. <article-title>Correlation of proliferative activity with pathological features in breast carcinoma</article-title>. <source>Eur J Gynaecol Oncol</source>. <year>1989</year>; <volume>10</volume>: <fpage>433</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="pmid">2627976</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref066"><label>66</label><mixed-citation publication-type="journal"><name><surname>Cavanaugh</surname><given-names>PG</given-names></name>, <name><surname>Jia</surname><given-names>L</given-names></name>, <name><surname>Zou</surname><given-names>Y</given-names></name>, <name><surname>Nicolson</surname><given-names>GL</given-names></name>. <article-title>Transferrin receptor overexpression enhances transferrin responsiveness and the metastatic growth of a rat mammary adenocarcinoma cell line</article-title>. <source>Breast Cancer Res Treat</source>. <year>1999</year>; <volume>56</volume>: <fpage>203</fpage>&#x02013;<lpage>17</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1023/a:1006209714287</pub-id>
<pub-id pub-id-type="pmid">10573112</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref067"><label>67</label><mixed-citation publication-type="journal"><name><surname>Martin</surname><given-names>BT</given-names></name>, <name><surname>Kleiber</surname><given-names>K</given-names></name>, <name><surname>Wixler</surname><given-names>V</given-names></name>, <name><surname>Raab</surname><given-names>M</given-names></name>, <name><surname>Zimmer</surname><given-names>B</given-names></name>, <name><surname>Kaufmann</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>FHL2 regulates cell cycle-dependent and doxorubicin-induced p21Cip1/Waf1 expression in breast cancer cells</article-title>. <source>Cell Cycle</source>. <year>2007</year>; <volume>6</volume>: <fpage>1779</fpage>&#x02013;<lpage>88</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.4161/cc.6.14.4448</pub-id>
<pub-id pub-id-type="pmid">17682292</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref068"><label>68</label><mixed-citation publication-type="journal"><name><surname>Choi</surname><given-names>YH</given-names></name>, <name><surname>Yoo</surname><given-names>YH</given-names></name>. <article-title>Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells</article-title>. <source>Oncol Rep</source>. <year>2012</year>; <volume>28</volume>: <fpage>2163</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3892/or.2012.2060</pub-id>
<pub-id pub-id-type="pmid">23023313</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref069"><label>69</label><mixed-citation publication-type="journal"><name><surname>Mackay</surname><given-names>A</given-names></name>, <name><surname>Urruticoechea</surname><given-names>A</given-names></name>, <name><surname>Dixon</surname><given-names>JM</given-names></name>, <name><surname>Dexter</surname><given-names>T</given-names></name>, <name><surname>Fenwick</surname><given-names>K</given-names></name>, <name><surname>Ashworth</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Molecular response to aromatase inhibitor treatment in primary breast cancer</article-title>. <source>Breast Cancer Res</source>. <year>2007</year>; <volume>9</volume>: <fpage>R37</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/bcr1732</pub-id>
<pub-id pub-id-type="pmid">17555561</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref070"><label>70</label><mixed-citation publication-type="journal"><name><surname>Yakes</surname><given-names>FM</given-names></name>, <name><surname>Chinratanalab</surname><given-names>W</given-names></name>, <name><surname>Ritter</surname><given-names>CA</given-names></name>, <name><surname>King</surname><given-names>W</given-names></name>, <name><surname>Seelig</surname><given-names>S</given-names></name>, <name><surname>Arteaga</surname><given-names>CL</given-names></name>. <article-title>Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action</article-title>. <source>Cancer Res</source>. <year>2002</year>; <volume>62</volume>: <fpage>4132</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="pmid">12124352</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref071"><label>71</label><mixed-citation publication-type="journal"><name><surname>Vera-Ramirez</surname><given-names>L</given-names></name>, <name><surname>Sanchez-Rovira</surname><given-names>P</given-names></name>, <name><surname>Ramirez-Tortosa</surname><given-names>CL</given-names></name>, <name><surname>Quiles</surname><given-names>JL</given-names></name>, <name><surname>Ramirez-Tortosa</surname><given-names>M</given-names></name>, <name><surname>Lorente</surname><given-names>JA</given-names></name>. <article-title>Transcriptional shift identifies a set of genes driving breast cancer chemoresistance</article-title>. <source>PLoS One</source>. <year>2013</year>; <volume>8</volume>: <fpage>e53983</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0053983</pub-id>
<pub-id pub-id-type="pmid">23326553</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref072"><label>72</label><mixed-citation publication-type="journal"><name><surname>Petrosyan</surname><given-names>V</given-names></name>, <name><surname>Dobrolecki</surname><given-names>LE</given-names></name>, <name><surname>Thistlethwaite</surname><given-names>L</given-names></name>, <name><surname>Lewis</surname><given-names>AN</given-names></name>, <name><surname>Sallas</surname><given-names>C</given-names></name>, <name><surname>Srinivasan</surname><given-names>RR</given-names></name>, <etal>et al</etal>. <article-title>Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach</article-title>. <source>iScience</source>. <year>2023</year>; <volume>26</volume>: <fpage>105799</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.isci.2022.105799</pub-id>
<pub-id pub-id-type="pmid">36619972</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref073"><label>73</label><mixed-citation publication-type="journal"><name><surname>Pulaski</surname><given-names>BA</given-names></name>, <name><surname>Ostrand-Rosenberg</surname><given-names>S</given-names></name>. <article-title>Mouse 4T1 breast tumor model</article-title>. <source>Curr Protoc Immunol</source>. <year>2001</year>; Chapter 20: Unit 20 2. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/0471142735.im2002s39</pub-id>
<pub-id pub-id-type="pmid">18432775</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref074"><label>74</label><mixed-citation publication-type="journal"><name><surname>Uluckan</surname><given-names>O</given-names></name>, <name><surname>Eagleton</surname><given-names>MC</given-names></name>, <name><surname>Floyd</surname><given-names>DH</given-names></name>, <name><surname>Morgan</surname><given-names>EA</given-names></name>, <name><surname>Hirbe</surname><given-names>AC</given-names></name>, <name><surname>Kramer</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice</article-title>. <source>J Cell Biochem</source>. <year>2008</year>; <volume>104</volume>: <fpage>1311</fpage>&#x02013;<lpage>23</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/jcb.21709</pub-id>
<pub-id pub-id-type="pmid">18260128</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref075"><label>75</label><mixed-citation publication-type="journal"><name><surname>Rudkouskaya</surname><given-names>A</given-names></name>, <name><surname>Sinsuebphon</surname><given-names>N</given-names></name>, <name><surname>Ochoa</surname><given-names>M</given-names></name>, <name><surname>Chen</surname><given-names>SJ</given-names></name>, <name><surname>Mazurkiewicz</surname><given-names>JE</given-names></name>, <name><surname>Intes</surname><given-names>X</given-names></name>, <etal>et al</etal>. <article-title>Multiplexed non-invasive tumor imaging of glucose metabolism and receptor-ligand engagement using dark quencher FRET acceptor</article-title>. <source>Theranostics</source>. <year>2020</year>; <volume>10</volume>: <fpage>10309</fpage>&#x02013;<lpage>25</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.7150/thno.45825</pub-id>
<pub-id pub-id-type="pmid">32929350</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref076"><label>76</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>C</given-names></name>, <name><surname>Liu</surname><given-names>P</given-names></name>, <name><surname>Duan</surname><given-names>X</given-names></name>, <name><surname>Cheng</surname><given-names>M</given-names></name>, <name><surname>Xu</surname><given-names>LX</given-names></name>. <article-title>Deferoxamine-induced high expression of TfR1 and DMT1 enhanced iron uptake in triple-negative breast cancer cells by activating IL-6/PI3K/AKT pathway</article-title>. <source>Onco Targets Ther</source>. <year>2019</year>; <volume>12</volume>: <fpage>4359</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">31213851</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref077"><label>77</label><mixed-citation publication-type="journal"><name><surname>De Bortoli</surname><given-names>M</given-names></name>, <name><surname>Taverna</surname><given-names>E</given-names></name>, <name><surname>Maffioli</surname><given-names>E</given-names></name>, <name><surname>Casalini</surname><given-names>P</given-names></name>, <name><surname>Crisafi</surname><given-names>F</given-names></name>, <name><surname>Kumar</surname><given-names>V</given-names></name>, <etal>et al</etal>. <article-title>Lipid accumulation in human breast cancer cells injured by iron depletors</article-title>. <source>J Exp Clin Cancer Res</source>. <year>2018</year>; <volume>37</volume>: <fpage>75</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s13046-018-0737-z</pub-id>
<pub-id pub-id-type="pmid">29615075</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref078"><label>78</label><mixed-citation publication-type="journal"><name><surname>Tajima</surname><given-names>S</given-names></name>, <name><surname>Ikeda</surname><given-names>Y</given-names></name>, <name><surname>Sawada</surname><given-names>K</given-names></name>, <name><surname>Yamano</surname><given-names>N</given-names></name>, <name><surname>Horinouchi</surname><given-names>Y</given-names></name>, <name><surname>Kihira</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice</article-title>. <source>Am J Physiol Endocrinol Metab</source>. <year>2012</year>; <volume>302</volume>: <fpage>E77</fpage>&#x02013;<lpage>86</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1152/ajpendo.00033.2011</pub-id>
<pub-id pub-id-type="pmid">21917632</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref079"><label>79</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>TS</given-names></name>, <name><surname>Shiao</surname><given-names>MS</given-names></name>, <name><surname>Pan</surname><given-names>CC</given-names></name>, <name><surname>Chau</surname><given-names>LY</given-names></name>. <article-title>Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice</article-title>. <source>Circulation</source>. <year>1999</year>; <volume>99</volume>: <fpage>1222</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/01.cir.99.9.1222</pub-id>
<pub-id pub-id-type="pmid">10069791</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref080"><label>80</label><mixed-citation publication-type="journal"><name><surname>Ferreira</surname><given-names>C</given-names></name>, <name><surname>Santambrogio</surname><given-names>P</given-names></name>, <name><surname>Martin</surname><given-names>ME</given-names></name>, <name><surname>Andrieu</surname><given-names>V</given-names></name>, <name><surname>Feldmann</surname><given-names>G</given-names></name>, <name><surname>Henin</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>H ferritin knockout mice: a model of hyperferritinemia in the absence of iron overload</article-title>. <source>Blood</source>. <year>2001</year>; <volume>98</volume>: <fpage>525</fpage>&#x02013;<lpage>32</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1182/blood.v98.3.525</pub-id>
<pub-id pub-id-type="pmid">11468145</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref081"><label>81</label><mixed-citation publication-type="journal"><name><surname>He</surname><given-names>XY</given-names></name>, <name><surname>Fan</surname><given-names>X</given-names></name>, <name><surname>Qu</surname><given-names>L</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Jiang</surname><given-names>L</given-names></name>, <name><surname>Sang</surname><given-names>LJ</given-names></name>, <etal>et al</etal>. <article-title>LncRNA modulates Hippo-YAP signaling to reprogram iron metabolism</article-title>. <source>Nat Commun</source>. <year>2023</year>; <volume>14</volume>: <fpage>2253</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-023-37871-5</pub-id>
<pub-id pub-id-type="pmid">37080959</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref082"><label>82</label><mixed-citation publication-type="journal"><name><surname>Chaston</surname><given-names>TB</given-names></name>, <name><surname>Lovejoy</surname><given-names>DB</given-names></name>, <name><surname>Watts</surname><given-names>RN</given-names></name>, <name><surname>Richardson</surname><given-names>DR</given-names></name>. <article-title>Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311</article-title>. <source>Clin Cancer Res</source>. <year>2003</year>; <volume>9</volume>: <fpage>402</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="pmid">12538494</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref083"><label>83</label><mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>DT</given-names></name>, <name><surname>Trowbridge</surname><given-names>IS</given-names></name>, <name><surname>Harris</surname><given-names>AL</given-names></name>. <article-title>Effects of transferrin receptor blockade on cancer cell proliferation and hypoxia-inducible factor function and their differential regulation by ascorbate</article-title>. <source>Cancer Res</source>. <year>2006</year>; <volume>66</volume>: <fpage>2749</fpage>&#x02013;<lpage>56</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-3857</pub-id>
<pub-id pub-id-type="pmid">16510596</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref084"><label>84</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>M</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Lu</surname><given-names>S</given-names></name>, <name><surname>He</surname><given-names>C</given-names></name>, <name><surname>Wang</surname><given-names>C</given-names></name>, <name><surname>Wang</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Erastin triggers autophagic death of breast cancer cells by increasing intracellular iron levels</article-title>. <source>Oncol Lett</source>. <year>2020</year>; <volume>20</volume>: <fpage>57</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3892/ol.2020.11918</pub-id>
<pub-id pub-id-type="pmid">32793311</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref085"><label>85</label><mixed-citation publication-type="journal"><name><surname>Moore</surname><given-names>A</given-names></name>, <name><surname>Basilion</surname><given-names>JP</given-names></name>, <name><surname>Chiocca</surname><given-names>EA</given-names></name>, <name><surname>Weissleder</surname><given-names>R</given-names></name>. <article-title>Measuring transferrin receptor gene expression by NMR imaging</article-title>. <source>Biochim Biophys Acta</source>. <year>1998</year>; <volume>1402</volume>: <fpage>239</fpage>&#x02013;<lpage>49</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0167-4889(98)00002-0</pub-id>
<pub-id pub-id-type="pmid">9606982</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref086"><label>86</label><mixed-citation publication-type="journal"><name><surname>Naves</surname><given-names>MA</given-names></name>, <name><surname>Graminha</surname><given-names>AE</given-names></name>, <name><surname>Vegas</surname><given-names>LC</given-names></name>, <name><surname>Luna-Dulcey</surname><given-names>L</given-names></name>, <name><surname>Honorato</surname><given-names>J</given-names></name>, <name><surname>Menezes</surname><given-names>ACS</given-names></name>, <etal>et al</etal>. <article-title>Transport of the Ruthenium Complex [Ru(GA)(dppe)2]PF6 into Triple-Negative Breast Cancer Cells Is Facilitated by Transferrin Receptors</article-title>. <source>Mol Pharm</source>. <year>2019</year>; <volume>16</volume>: <fpage>1167</fpage>&#x02013;<lpage>83</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b01154</pub-id>
<pub-id pub-id-type="pmid">30633527</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref087"><label>87</label><mixed-citation publication-type="journal"><name><surname>Reed</surname><given-names>NA</given-names></name>, <name><surname>Raliya</surname><given-names>R</given-names></name>, <name><surname>Tang</surname><given-names>R</given-names></name>, <name><surname>Xu</surname><given-names>B</given-names></name>, <name><surname>Mixdorf</surname><given-names>M</given-names></name>, <name><surname>Achilefu</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Electrospray Functionalization of Titanium Dioxide Nanoparticles with Transferrin for Cerenkov Radiation Induced Cancer Therapy</article-title>. <source>ACS Appl Bio Mater</source>. <year>2019</year>; <volume>2</volume>: <fpage>1141</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/acsabm.8b00755</pub-id>
<pub-id pub-id-type="pmid">31214665</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref088"><label>88</label><mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>H</given-names></name>, <name><surname>Yang</surname><given-names>C</given-names></name>, <name><surname>Jian</surname><given-names>L</given-names></name>, <name><surname>Guo</surname><given-names>S</given-names></name>, <name><surname>Chen</surname><given-names>R</given-names></name>, <name><surname>Li</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Sulfasalazine&#x02011;induced ferroptosis in breast cancer cells is reduced by the inhibitory effect of estrogen receptor on the transferrin receptor</article-title>. <source>Oncol Rep</source>. <year>2019</year>; <volume>42</volume>: <fpage>826</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">31173262</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref089"><label>89</label><mixed-citation publication-type="journal"><name><surname>Loibl</surname><given-names>S</given-names></name>, <name><surname>Poortmans</surname><given-names>P</given-names></name>, <name><surname>Morrow</surname><given-names>M</given-names></name>, <name><surname>Denkert</surname><given-names>C</given-names></name>, <name><surname>Curigliano</surname><given-names>G</given-names></name>. <article-title>Breast cancer</article-title>. <source>Lancet</source>. <year>2021</year>; <volume>397</volume>: <fpage>1750</fpage>&#x02013;<lpage>69</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(20)32381-3</pub-id>
<pub-id pub-id-type="pmid">33812473</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref090"><label>90</label><mixed-citation publication-type="journal"><name><surname>Fryknas</surname><given-names>M</given-names></name>, <name><surname>Zhang</surname><given-names>X</given-names></name>, <name><surname>Bremberg</surname><given-names>U</given-names></name>, <name><surname>Senkowski</surname><given-names>W</given-names></name>, <name><surname>Olofsson</surname><given-names>MH</given-names></name>, <name><surname>Brandt</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Iron chelators target both proliferating and quiescent cancer cells</article-title>. <source>Sci Rep</source>. <year>2016</year>; <volume>6</volume>: <fpage>38343</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/srep38343</pub-id>
<pub-id pub-id-type="pmid">27924826</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref091"><label>91</label><mixed-citation publication-type="journal"><name><surname>Hoke</surname><given-names>EM</given-names></name>, <name><surname>Maylock</surname><given-names>CA</given-names></name>, <name><surname>Shacter</surname><given-names>E</given-names></name>. <article-title>Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin</article-title>. <source>Free Radic Biol Med</source>. <year>2005</year>; <volume>39</volume>: <fpage>403</fpage>&#x02013;<lpage>11</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2005.03.029</pub-id>
<pub-id pub-id-type="pmid">15993339</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref092"><label>92</label><mixed-citation publication-type="journal"><name><surname>Liang</surname><given-names>W</given-names></name>, <name><surname>Ferrara</surname><given-names>N</given-names></name>. <article-title>Iron Metabolism in the Tumor Microenvironment: Contributions of Innate Immune Cells</article-title>. <source>Front Immunol</source>. <year>2020</year>; <volume>11</volume>: <fpage>626812</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fimmu.2020.626812</pub-id>
<pub-id pub-id-type="pmid">33679721</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref093"><label>93</label><mixed-citation publication-type="journal"><name><surname>Liang</surname><given-names>W</given-names></name>, <name><surname>Li</surname><given-names>Q</given-names></name>, <name><surname>Ferrara</surname><given-names>N</given-names></name>. <article-title>Metastatic growth instructed by neutrophil-derived transferrin</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2018</year>; <volume>115</volume>: <fpage>11060</fpage>&#x02013;<lpage>5</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.1811717115</pub-id>
<pub-id pub-id-type="pmid">30301793</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref094"><label>94</label><mixed-citation publication-type="journal"><name><surname>Cappellini</surname><given-names>MD</given-names></name>, <name><surname>Porter</surname><given-names>J</given-names></name>, <name><surname>El-Beshlawy</surname><given-names>A</given-names></name>, <name><surname>Li</surname><given-names>CK</given-names></name>, <name><surname>Seymour</surname><given-names>JF</given-names></name>, <name><surname>Elalfy</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias</article-title>. <source>Haematologica</source>. <year>2010</year>; <volume>95</volume>: <fpage>557</fpage>&#x02013;<lpage>66</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3324/haematol.2009.014696</pub-id>
<pub-id pub-id-type="pmid">19951979</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref095"><label>95</label><mixed-citation publication-type="journal"><name><surname>Martin-Bastida</surname><given-names>A</given-names></name>, <name><surname>Ward</surname><given-names>RJ</given-names></name>, <name><surname>Newbould</surname><given-names>R</given-names></name>, <name><surname>Piccini</surname><given-names>P</given-names></name>, <name><surname>Sharp</surname><given-names>D</given-names></name>, <name><surname>Kabba</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson&#x02019;s disease</article-title>. <source>Sci Rep</source>. <year>2017</year>; <volume>7</volume>: <fpage>1398</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-017-01402-2</pub-id>
<pub-id pub-id-type="pmid">28469157</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref096"><label>96</label><mixed-citation publication-type="journal"><name><surname>Devos</surname><given-names>D</given-names></name>, <name><surname>Labreuche</surname><given-names>J</given-names></name>, <name><surname>Rascol</surname><given-names>O</given-names></name>, <name><surname>Corvol</surname><given-names>JC</given-names></name>, <name><surname>Duhamel</surname><given-names>A</given-names></name>, <name><surname>Guyon Delannoy</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Trial of Deferiprone in Parkinson&#x02019;s Disease</article-title>. <source>N Engl J Med</source>. <year>2022</year>; <volume>387</volume>: <fpage>2045</fpage>&#x02013;<lpage>55</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa2209254</pub-id>
<pub-id pub-id-type="pmid">36449420</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref097"><label>97</label><mixed-citation publication-type="journal"><name><surname>Weigel</surname><given-names>KJ</given-names></name>, <name><surname>Lynch</surname><given-names>SG</given-names></name>, <name><surname>LeVine</surname><given-names>SM</given-names></name>. <article-title>Iron chelation and multiple sclerosis</article-title>. <source>ASN Neuro</source>. <year>2014</year>; <volume>6</volume>: <fpage>e00136</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1042/AN20130037</pub-id>
<pub-id pub-id-type="pmid">24397846</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref098"><label>98</label><mixed-citation publication-type="journal"><name><surname>Salvarani</surname><given-names>C</given-names></name>, <name><surname>Baricchi</surname><given-names>R</given-names></name>, <name><surname>Lasagni</surname><given-names>D</given-names></name>, <name><surname>Boiardi</surname><given-names>L</given-names></name>, <name><surname>Piccinini</surname><given-names>R</given-names></name>, <name><surname>Brunati</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis</article-title>. <source>Rheumatol Int</source>. <year>1996</year>; <volume>16</volume>: <fpage>45</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/BF01816434</pub-id>
<pub-id pub-id-type="pmid">8853224</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref099"><label>99</label><mixed-citation publication-type="journal"><name><surname>Saxena</surname><given-names>D</given-names></name>, <name><surname>Spino</surname><given-names>M</given-names></name>, <name><surname>Tricta</surname><given-names>F</given-names></name>, <name><surname>Connelly</surname><given-names>J</given-names></name>, <name><surname>Cracchiolo</surname><given-names>BM</given-names></name>, <name><surname>Hanauske</surname><given-names>AR</given-names></name>, <etal>et al</etal>. <article-title>Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial</article-title>. <source>PLoS One</source>. <year>2016</year>; <volume>11</volume>: <fpage>e0154842</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0154842</pub-id>
<pub-id pub-id-type="pmid">27191165</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref100"><label>100</label><mixed-citation publication-type="journal"><name><surname>Mody</surname><given-names>K</given-names></name>, <name><surname>Mansfield</surname><given-names>AS</given-names></name>, <name><surname>Vemireddy</surname><given-names>L</given-names></name>, <name><surname>Nygren</surname><given-names>P</given-names></name>, <name><surname>Gulbo</surname><given-names>J</given-names></name>, <name><surname>Borad</surname><given-names>M</given-names></name>. <article-title>A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors</article-title>. <source>Invest New Drugs</source>. <year>2019</year>; <volume>37</volume>: <fpage>684</fpage>&#x02013;<lpage>92</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s10637-018-0703-9</pub-id>
<pub-id pub-id-type="pmid">30460505</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref101"><label>101</label><mixed-citation publication-type="journal"><name><surname>Yamasaki</surname><given-names>T</given-names></name>, <name><surname>Terai</surname><given-names>S</given-names></name>, <name><surname>Sakaida</surname><given-names>I</given-names></name>. <article-title>Deferoxamine for advanced hepatocellular carcinoma</article-title>. <source>N Engl J Med</source>. <year>2011</year>; <volume>365</volume>: <fpage>576</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMc1105726</pub-id>
<pub-id pub-id-type="pmid">21830988</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref102"><label>102</label><mixed-citation publication-type="journal"><name><surname>Crapper McLachlan</surname><given-names>DR</given-names></name>, <name><surname>Dalton</surname><given-names>AJ</given-names></name>, <name><surname>Kruck</surname><given-names>TP</given-names></name>, <name><surname>Bell</surname><given-names>MY</given-names></name>, <name><surname>Smith</surname><given-names>WL</given-names></name>, <name><surname>Kalow</surname><given-names>W</given-names></name>, <etal>et al</etal>. <article-title>Intramuscular desferrioxamine in patients with Alzheimer&#x02019;s disease</article-title>. <source>Lancet</source>. <year>1991</year>; <volume>337</volume>: <fpage>1304</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/0140-6736(91)92978-b</pub-id>
<pub-id pub-id-type="pmid">1674295</pub-id>
</mixed-citation></ref><ref id="pone.0293700.ref103"><label>103</label><mixed-citation publication-type="journal"><name><surname>Saeki</surname><given-names>I</given-names></name>, <name><surname>Yamamoto</surname><given-names>N</given-names></name>, <name><surname>Yamasaki</surname><given-names>T</given-names></name>, <name><surname>Takami</surname><given-names>T</given-names></name>, <name><surname>Maeda</surname><given-names>M</given-names></name>, <name><surname>Fujisawa</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma</article-title>. <source>World J Gastroenterol</source>. <year>2016</year>; <volume>22</volume>: <fpage>8967</fpage>&#x02013;<lpage>77</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3748/wjg.v22.i40.8967</pub-id>
<pub-id pub-id-type="pmid">27833388</pub-id>
</mixed-citation></ref></ref-list></back></article>
